<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005185" GROUP_ID="HTN" ID="938004090110370847" MERGED_FROM="" MODIFIED="2011-09-06 23:40:17 +0200" MODIFIED_BY="Ciprian Jauca" REVIEW_NO="A043" REVMAN_SUB_VERSION="5.1.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.2">
<COVER_SHEET MODIFIED="2011-09-06 23:40:17 +0200" MODIFIED_BY="Ciprian Jauca">
<TITLE>Thiazide diuretics and the risk of hip fracture</TITLE>
<CONTACT MODIFIED="2011-09-06 23:40:17 +0200" MODIFIED_BY="Ciprian Jauca"><PERSON ID="448495C282E26AA200991D5629644835" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>KoKo</FIRST_NAME><LAST_NAME>Aung</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>kaung1@jhu.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Dr</ADDRESS_1><ADDRESS_2>MC 7879</ADDRESS_2><CITY>San Antonio</CITY><ZIP>78229</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 7873268</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-09-06 23:40:17 +0200" MODIFIED_BY="Ciprian Jauca"><PERSON ID="448495C282E26AA200991D5629644835" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>KoKo</FIRST_NAME><LAST_NAME>Aung</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>kaung1@jhu.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Dr</ADDRESS_1><ADDRESS_2>MC 7879</ADDRESS_2><CITY>San Antonio</CITY><ZIP>78229</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 7873268</PHONE_1></ADDRESS></PERSON><PERSON ID="44AC290C82E26AA200991D56EB4E0AE7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Thwe</FIRST_NAME><LAST_NAME>Htay</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>htayt@aol.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Dr</ADDRESS_1><ADDRESS_2>MC 7879</ADDRESS_2><CITY>San Antonio</CITY><ZIP>78229</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 4509100</PHONE_1><FAX_1>+1 210 4506008</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-08-31 19:01:44 -0500" MODIFIED_BY="Ciprian D Jauca">
<UP_TO_DATE>
<DATE DAY="1" MONTH="10" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="2" MONTH="4" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2011-08-31 19:02:12 -0500" MODIFIED_BY="Ciprian D Jauca"/>
<HISTORY MODIFIED="2011-08-31 19:02:12 -0500" MODIFIED_BY="Ciprian D Jauca">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-08-31 19:02:12 -0500" MODIFIED_BY="Ciprian D Jauca">
<DATE DAY="12" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Contact details updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-12 17:29:14 -0600" MODIFIED_BY="Ciprian Jauca">
<DATE DAY="12" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-11-23 23:16:38 -0600" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2010-11-23 23:16:38 -0600" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-11-23 23:16:38 -0600" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-11-23 23:16:22 -0600" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-11-23 23:16:22 -0600" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-04 18:46:08 -0500" MODIFIED_BY="Ciprian D Jauca">
<SUMMARY MODIFIED="2011-08-31 15:28:02 -0500" MODIFIED_BY="James M Wright">
<TITLE MODIFIED="2010-11-23 23:17:30 -0600" MODIFIED_BY="[Empty name]">Thiazide diuretics and hip fracture</TITLE>
<SUMMARY_BODY MODIFIED="2011-08-31 15:28:02 -0500" MODIFIED_BY="James M Wright">
<P>Twenty-one studies of observational nature with nearly four hundred thousand participants were included in this systematic review. Studies looked for an association between thiazide diuretic use and hip fracture. The majority of included studies have low to moderate risk of bias. Thiazide diuretic use was associated with a reduction in risk of hip fracture. Randomized controlled trials are needed to confirm these findings.  </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-09-04 18:18:28 -0500" MODIFIED_BY="Ciprian D Jauca">
<ABS_BACKGROUND MODIFIED="2010-11-17 16:18:24 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide diuretics are one of the most commonly prescribed antihypertensive agents worldwide. Thiazides reduce urinary calcium excretion. Chronic ingestion of thiazides is associated with higher bone mineral density. It has been suggested that thiazides may prevent hip fracture. However, there are concerns that diuretics, by increasing the risk of fall in elderly, could potentially negate its beneficial effects on hip fracture.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-08-31 18:00:55 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>To assess any association between the use of thiazide diuretics and the risk of hip fracture in adults.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-09-04 18:17:55 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>We searched eligible studies up to December 2008 in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts, the Database of Abstracts of Review of Effects (DARE) and reference lists of previous reviews and included studies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-08-31 18:11:15 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>All randomized controlled trials and observational studies, which assessed the association between thiazide diuretic use and hip fracture. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-08-31 18:03:18 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>Two review authors independently applied the selection criteria, extracted data and assessed risk of bias of each study selected.  The results were summarized descriptively and quantitatively. Cohort studies and case control studies were analysed separately.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-09-04 18:18:28 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>No randomized control trials were found. Twenty-one observational studies with nearly four hundred thousand participants were included. Six of them were cohort studies and 15 were case-control studies. Two cohort studies appear to involve the same cohort so there were only 5 unique ones. The risk of bias was assessed with the Newcastle-Ottawa Scale (NOS). Five cohort studies had low risk of bias and one had moderate risk of bias. Seven case control studies had low risk of bias and 8 had moderate risk of bias. Meta-analysis of cohort studies showed that thiazide use was associated with a reduction in risk of hip fracture by 24%, pooled RR 0.76 (95% CI 0.64-0.89; p = 0.0009). We chose not to provide a pooled summary statistics for case-control studies because of high heterogeneity (Tau<SUP>2</SUP> = 0.03, I<SUP>2 </SUP>= 62%, p = 0.0008).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-08-31 15:26:02 -0500" MODIFIED_BY="James M Wright">
<P>Thiazides appear to reduce the risk of hip fracture based on observational studies. Randomized controlled trials are needed to confirm these findings.  </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-09-04 18:46:08 -0500" MODIFIED_BY="Ciprian D Jauca">
<BACKGROUND MODIFIED="2011-09-04 18:19:28 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>Thiazide diuretics have been a cornerstone of antihypertensive therapy for longer than half a century. They have been proven in large scale randomized controlled trials (<LINK REF="REF-MRC-1985" TYPE="REFERENCE">MRC 1985</LINK>, <LINK REF="REF-SHEP-1991" TYPE="REFERENCE">SHEP 1991</LINK>, <LINK REF="REF-Hansson-1999" TYPE="REFERENCE">Hansson 1999</LINK>, <LINK REF="REF-ALLHAT-2000" TYPE="REFERENCE">ALLHAT 2000</LINK>, <LINK REF="REF-ALLHAT-2002" TYPE="REFERENCE">ALLHAT 2002</LINK>) and systematic reviews (<LINK REF="REF-Psaty-2003" TYPE="REFERENCE">Psaty 2003</LINK>, <LINK REF="REF-Wright-2009" TYPE="REFERENCE">Wright 2009</LINK>) to reduce cardiovascular morbidity and mortality, particularly related to stroke, in individuals with persistently elevated blood pressure. One of the benefits of thiazides outside of the cardiovascular system is their hypocalciuric effect.  In 1959, Lamberg and Kuhlbäck found that chlorothiazide and hydrochlorothiazide reduced the excretion of calcium in urine (<LINK REF="REF-Lamberg-1959" TYPE="REFERENCE">Lamberg 1959</LINK>). This effect was used to prevent recurrence of calcium containing urinary stones (<LINK REF="REF-Nassim-1965" TYPE="REFERENCE">Nassim 1965</LINK>). In 1973, Middler et al demonstrated in an experimental study that thiazide diuretics reduced urinary calcium excretion by about 40% in individuals with intact parathyroid glands (<LINK REF="REF-Middler-1973" TYPE="REFERENCE">Middler 1973</LINK>).</P>
<P>Epidemiological studies have associated chronic ingestion of thiazides with higher bone mineral density in both women and men (<LINK REF="STD-Wasnich-1983" TYPE="STUDY">Wasnich 1983</LINK>, <LINK REF="REF-Bauer-1993" TYPE="REFERENCE">Bauer 1993</LINK>, <LINK REF="REF-Morton-1994" TYPE="REFERENCE">Morton 1994</LINK>, <LINK REF="REF-Glynn-1995" TYPE="REFERENCE">Glynn 1995</LINK>).  A cohort study (<LINK REF="STD-LaCroix-2000" TYPE="STUDY">LaCroix 2000</LINK>) demonstrated that thiazide use preserved bone mineral density at the hip and spine in normotensive healthy men and women. In a randomized controlled trial of healthy women in their early menopause, bendroflumethiazide 5 mg/day for 6 months was associated with no reduction in bone mineral content of the forearms measured by single photon absorptiometry while a decrease of 2% per year took place in the placebo group (<LINK REF="REF-Transbol-1982" TYPE="REFERENCE">Transbol 1982</LINK>). The active treatment continued for a total of 2 years, followed by placebo in both bendroflumethiazide group and placebo group for one more year. At the end of 3 years, no difference in bone mineral content was found. A randomised, double-masked, placebo-controlled trial of chlorthalidone and bone loss in hypertensive postmenopausal women showed that after a mean duration of 2.6 years, chlorthalidone use, at doses of 12.5-25 mg/day, was associated with bone gain at the calcaneus and distal radius, and reduction of bone loss at proximal radius, resulting in an average increment for three appendicular sites of 0.9% per year (<LINK REF="REF-Wasnich-1995" TYPE="REFERENCE">Wasnich 1995</LINK>).  This study was conducted as a prospective ancillary study among women participating in SHEP (Systolic Hypertension in Elderly Program), a double-masked placebo controlled study employing a thiazide-like diuretic chlorthalidone, at the SHEP Center in Hawaii.</P>
<P>Whether the physiological effects of lowering urinary calcium excretion and slowing the reduction of bone mineral density lead to reduction in hip fractures, the most clinically important fracture related to osteoporosis in older adults, is uncertain.  While endocrinologists are interested in potential beneficial effects of thiazides on calcium metabolism and bone health, geriatricians are legitimately concerned about diuretics&#8217; potential effect on increasing the risk of falls in older adults.  A small case-control study on drug use and accidental falls in an intermediate care facility reported that the use of diuretics was significantly greater in the population who had fallen (<LINK REF="REF-Sobel-1983" TYPE="REFERENCE">Sobel 1983</LINK>).  A larger study, the St. Louis OASIS (Older Adult Service and Information System) found a statistically significant increase in odds of multiple falls in elderly users of diuretics, adjusted for age, gender, depression, cognitive impairment, use of antipsychotics, use of 5 other medications, and a few other variables (<LINK REF="REF-Cumming-1991" TYPE="REFERENCE">Cumming 1991</LINK>). The data on thiazide and non-thiazide diuretics were not separately reported in the paper.   </P>
<P>The beneficial effect of thiazides on bone density could potentially be offset by the increased in incidence of falls resulting in hip fracture, especially in the elderly caused by orthostatic hypotension (<LINK REF="REF-Myers-1978" TYPE="REFERENCE">Myers 1978</LINK>) or dizziness. Available studies within the last few decades have shown conflicting results regarding the effects of thiazides on the incidence of hip fracture (<LINK REF="STD-Heidrich-1991" TYPE="STUDY">Heidrich 1991</LINK>; <LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>). Nearly half a century ago, results of metabolic studies led to recommending thiazides to prevent bone loss (<LINK REF="REF-Rose-1966" TYPE="REFERENCE">Rose 1966</LINK>). Whether the beneficial effects on surrogate outcomes such as urinary calcium excretion and bone mineral density translate to a favourable hard outcome that matters to a patient, i.e., reduction of hip fracture, remains unclear. This warrants a systematic review of the available evidence regarding the effects of thiazides on risk of hip fracture.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-07-24 17:10:04 -0500" MODIFIED_BY="[Empty name]">
<P>The objective of this systematic review is to assess any association between the use of thiazide diuretics and the risk of hip fractures as compared to nonusers in adults.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-09-04 18:22:47 -0500" MODIFIED_BY="Ciprian D Jauca">
<SELECTION_CRITERIA MODIFIED="2011-09-04 18:20:27 -0500" MODIFIED_BY="Ciprian D Jauca">
<CRIT_STUDIES MODIFIED="2011-09-04 18:20:27 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>We recognized that randomized controlled trials specifically designed to compare thiazides and placebo or drugs for their effect on hip or other fractures may not exist since thiazide diuretics are primarily used as antihypertensive agents not as medications to prevent hip fracture. Moreover, the magnitude of the effect found in previous studies showed that a randomized controlled study of adequate power is unlikely to be pursued (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>). Such trials were searched for to be included if any were found. Because of the high likelihood of lack of such randomized controlled trials, we also searched for observational studies to be included in this review. Cohort studies comparing the incidence of hip fractures between one group taking thiazides and another not taking thiazides were included. Case-control studies in which use and non-use of thiazides are compared between the group of patients with hip fractures and the group of age- and sex-matched controls without hip fracture were also included in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-11-17 16:39:32 -0600" MODIFIED_BY="[Empty name]">
<P>The participants of this review were adult males and females, aged 40 and above, who took thiazide diuretics and comparators for hypertension or any other reasons.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-21 23:48:03 -0600" MODIFIED_BY="[Empty name]">
<P>The intervention of interest was the use of any thiazide diuretic, including hydrochlorothiazide, chlorthalidone, bendroflumethiazide, chlorothiazide, cyclothiazide, methyclothiazide, hydroflumethiazide, trichlormethiazide, benzthiazide, polythiazide, buthiazide, cyclopenthiazide, metolazone, quinethazone, fenquizone, clorexolone, clopamide, indapamide, diapamide, isodapamide, mefruside and xipamide.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-17 16:40:25 -0600" MODIFIED_BY="[Empty name]">
<P>The primary outcome measure was the incidence of hip fracture.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-09-04 18:20:53 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>Electronic searches of the following databases were conducted: Medline, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), the Cumulative Index to Nursing and Allied Health Literature (CINAHL), International Pharmaceutical Abstracts, and the Database of Abstracts of Reviews of Effects (DARE). The search was be limited to human. No restrictions were made based upon language of the report. A modified, expanded version of the standard search strategy of the Hypertension Group for randomized controlled trials and observational studies, with additional terms related to hip fracture and thiazide diuretic agents were used to identify the relevant articles. The following search terms were used: DIURETICS, THIAZIDE (MeSH), HYDROCHLOROTHIAZIDE (MeSH), CHLORTHALIDONE (MeSH), BENDROFLUMETHIAZIDE (MeSH), CHLOROTHIAZIDE (MeSH), cyclothiazide.tw, METHYCLOTHIAZIDE (MeSH), HYDROFLUMETHIAZIDE (MeSH), TRICHLORMETHIAZIDE (MeSH), benzthiazide.tw, POLYTHIAZIDE (MeSH), cyclopenthiazide.tw, buthiazide.tw, metolazone.tw, quinethazone.tw, fenquizone.tw, clorexolone.tw, clopamide.tw, indapamide.tw, diapamide.tw, isodapamide.tw, mefruside.tw, xipamide.tw, HIP FRACTURES (MeSH), (hip adj25 fracture$).tw, FEMORAL NECK FRACTURES (MeSH), ((femur$ or femoral$) adj25 neck adj25 fracture$).tw, (hip$ or femur$ or femoral$ or trochant$ or pertrochant$ or intertrochant$ or subtrochant$ or intracapsular$ or extracapsular$).tw, and FRACTURES (MeSH). Search terms were modified to match EMTREE keywords when using EMBASE. Ongoing clinical trials and unpublished studies were searched via the worldwide web on the following sites: http://www.controlled-trials.com, http://www.clinicaltrials.gov, http://www.centerwatch.com.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-09-04 18:22:47 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>
<B>Identification of studies:</B> Using the search strategy described above, two reviewers independently selected studies for inclusion in the review. The initial searches of all the databases were performed to identify citations with potential relevance. The articles whose titles and/or abstracts were clearly irrelevant were excluded in initial screening. The full texts of remaining articles were then retrieved. The reference lists of retrieved articles, reviews and texts were searched for additional citations.</P>
<P>
<B>Assessment of methodological quality of included studies:</B> Each included study was classified as a randomized controlled trial or observational study, and the risk of bias assessed for each study. For cohort studies, selection of exposed and nonexposed cohort, comparability of cohorts, assessment of outcome, and adequacy of follow-up were addressed. For case-control studies, selection of cases and controls, comparability of cases and controls, and ascertainment of exposure were emphasized. The Newcastle-Ottawa Scale (NOS) was used for assessing the risk of bias in observational studies (<LINK REF="REF-Wells" TYPE="REFERENCE">Wells</LINK>).</P>
<P>
<B>Data extraction and synthesis:</B> Two reviewers independently performed data extraction and the results were cross-checked by double-data entry. Disagreements were resolved by discussion and consensus. The information collected from each study included study design, time and setting of study, study population, and methods of ascertainment of thiazide diuretic use and hip fracture. Data entry and analyses were performed using the Cochrane Review Manager software (RevMan 5; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008). Randomized and observational (non-randomized) studies were planned to be analysed separately as a direct comparison between the estimates of observational studies and randomized trials can be misleading. Non-randomized comparisons can both exaggerate and underemphasize compared to randomized comparisons but the magnitude and direction of the effect are inconsistent. Among observational studies, cohort and case-controlled studies were analysed separately since case control studies could give different estimates to cohort studies and the direction of the discrepancy tend to be inconsistent (<LINK REF="REF-Reeves-1999" TYPE="REFERENCE">Reeves 1999</LINK>). Generic inverse variance method was used. Standard error around log [risk ratio] and log [odds ratio] were calculated by dividing the difference between log [upper confidence interval] and log [risk ratio] or log [odds ratio] by 1.96. Heterogeneity between trials was tested using a standard Chi-squared test and the newer concept of <I>I<SUP>2</SUP>
</I> (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>) as measures of inconsistency. Formal meta-analytic techniques were applied. The results were reported as risk ratio or odds ratio with corresponding 95% confidence intervals. Random effects model of DerSimonian and Laird was used when there was evidence of heterogeneity between studies (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). Fixed-effect model (Mantel Haenszel methods) was used when there was no evidence of heterogeneity (<LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>). A funnel plot of precision in the estimation of underlying treatment effect was used to check the publication bias.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-09-04 18:46:08 -0500" MODIFIED_BY="Ciprian D Jauca">
<STUDY_DESCRIPTION MODIFIED="2011-08-31 18:30:38 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>A total of 267 potential relevant citations were screened for retrieval.  Among those, 194 were excluded because patients, intervention or outcome did not meet the inclusion criteria. 73 citations were then retrieved for detailed evaluation. 42 duplicates were excluded. The remaining 31 citations were evaluated for details. 14 citations were added from bibliography of articles evaluated. A total of 45 full text articles were reviewed. 24 of them were excluded. The reasons for exclusion were using bone density and not hip fracture as the outcome measure, lack of data for hip fracture instead of all fractures, lack of data on thiazide use instead of all diuretics, and not being original investigations.</P>
<P>We identified no randomized controlled trials and 21 observational studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), of which 6 were cohort studies (<LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK>, <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK>, <LINK REF="STD-Feskanich-1997" TYPE="STUDY">Feskanich 1997</LINK>, <LINK REF="STD-Guo-1998" TYPE="STUDY">Guo 1998</LINK>, <LINK REF="STD-LaCroix-1990" TYPE="STUDY">LaCroix 1990</LINK>, <LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>) and 15 were case-control studies (<LINK REF="STD-Barengolts-2001" TYPE="STUDY">Barengolts 2001</LINK>, <LINK REF="STD-Cumming-1993" TYPE="STUDY">Cumming 1993</LINK>, <LINK REF="STD-Felson-1991" TYPE="STUDY">Felson 1991</LINK>, <LINK REF="STD-Grisso-1994" TYPE="STUDY">Grisso 1994</LINK>, <LINK REF="STD-Heidrich-1991" TYPE="STUDY">Heidrich 1991</LINK>, <LINK REF="STD-Herings-1996" TYPE="STUDY">Herings 1996</LINK>, <LINK REF="STD-Jensen1991" TYPE="STUDY">Jensen1991</LINK>, <LINK REF="STD-Paganini_x002d_Hill-1981" TYPE="STUDY">Paganini-Hill 1981</LINK>, <LINK REF="STD-Rashiq-1986" TYPE="STUDY">Rashiq 1986</LINK>, <LINK REF="STD-Ray-1989" TYPE="STUDY">Ray 1989</LINK>, <LINK REF="STD-Rejnmark-2005" TYPE="STUDY">Rejnmark 2005</LINK>, <LINK REF="STD-Stevens-1989" TYPE="STUDY">Stevens 1989</LINK>, <LINK REF="STD-Taggart-1988" TYPE="STUDY">Taggart 1988</LINK>, <LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>, <LINK REF="STD-Weiland-1997" TYPE="STUDY">Weiland 1997</LINK>).</P>
<P>The cohort studies of <LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK> and <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK> appear to originate from the same cohort and were conducted by the same group of investigators. The minor variations in the numbers of participants and duration of follow-up appear to be as a result of different time of analyses. Adjusted relative risks of hip fracture in current thiazide user reported in these two studies were very similar: 0.82 (95% CI, 0.56-1.12) in <LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK>, 0.8 (95% CI, 0.6-1.2) in <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK>. Hence, the 6 cohort studies we reviewed were essentially 5 cohort studies. Descriptives were extracted from all 6 cohort studies but data from only 5 unique cohort studies were used in quantitative analyses (calculating median risk of bias scores and conducting meta-analysis).</P>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-08-31 18:30:38 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>The 21 studies included a total of 399,362 participants (121,965 in cohort studies and 277,397 in case-control studies) from seven countries. Ten studies were carried out in the United States (<LINK REF="STD-Barengolts-2001" TYPE="STUDY">Barengolts 2001</LINK>, <LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK>, <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK>, <LINK REF="STD-Feskanich-1997" TYPE="STUDY">Feskanich 1997</LINK>, <LINK REF="STD-Guo-1998" TYPE="STUDY">Guo 1998</LINK>, <LINK REF="STD-Heidrich-1991" TYPE="STUDY">Heidrich 1991</LINK>, <LINK REF="STD-Jensen1991" TYPE="STUDY">Jensen1991</LINK>, <LINK REF="STD-LaCroix-1990" TYPE="STUDY">LaCroix 1990</LINK>, <LINK REF="STD-Paganini_x002d_Hill-1981" TYPE="STUDY">Paganini-Hill 1981</LINK>, <LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>), 3 in the United Kingdom (<LINK REF="STD-Rashiq-1986" TYPE="STUDY">Rashiq 1986</LINK>, <LINK REF="STD-Stevens-1989" TYPE="STUDY">Stevens 1989</LINK>, <LINK REF="STD-Taggart-1988" TYPE="STUDY">Taggart 1988</LINK>), 2 in Denmark (<LINK REF="STD-Jensen1991" TYPE="STUDY">Jensen1991</LINK>, <LINK REF="STD-Rejnmark-2005" TYPE="STUDY">Rejnmark 2005</LINK>), 2 in Netherlands (<LINK REF="STD-Herings-1996" TYPE="STUDY">Herings 1996</LINK>, <LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>), 1 in Australia (<LINK REF="STD-Cumming-1993" TYPE="STUDY">Cumming 1993</LINK>), 1 in Canada (<LINK REF="STD-Ray-1989" TYPE="STUDY">Ray 1989</LINK>), 1 in Germany (<LINK REF="STD-Weiland-1997" TYPE="STUDY">Weiland 1997</LINK>), and 1 in Sweden (<LINK REF="STD-Guo-1998" TYPE="STUDY">Guo 1998</LINK>). The studies were published between 1981 and 2005.</P>
<P>
<B>Sponsorship</B>
</P>
<P>Of the 21 studies, 13 declared sponsorship of studies. In the United States and Canada, the United States Public Health Service Grants, National Institute of Health, the United States Department of Agriculture, the National Institute of Aging, the Robert Wood Johnson Foundation, Foundation for Group Health Cooperative, the Center for Disease Control, National Institute for Drug Abuse, and the United States Food and Drug Administration sponsored grants to support the studies.  In Sweden, Swedish Medical Research Council, Swedish Council for Social Research, Swedish Municipal Pension Institute, National Corporation of Swedish Pharmacies&#8217; Fund for Research and Studies in Health Economics and Social Pharmacies, the Torsten and Ragnar Söderbergs Foundation, and the Foundation for Medical Research sponsored grants support the study (<LINK REF="STD-Guo-1998" TYPE="STUDY">Guo 1998</LINK>). One study from Germany (<LINK REF="STD-Weiland-1997" TYPE="STUDY">Weiland 1997</LINK>) was funded by Sandoz AG, Nürnberg. One study from Netherlands (<LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>) declared no external funding. Co-investigators from one American (<LINK REF="STD-Heidrich-1991" TYPE="STUDY">Heidrich 1991</LINK>) and one Canadian study (<LINK REF="STD-Ray-1989" TYPE="STUDY">Ray 1989</LINK>) included Burroughs Wellcome Scholars in Pharmacoepidemiology.  </P>
<P>Eight studies did not declare sponsorship in their publications. Three were from U.K. (<LINK REF="STD-Rashiq-1986" TYPE="STUDY">Rashiq 1986</LINK>, <LINK REF="STD-Stevens-1989" TYPE="STUDY">Stevens 1989</LINK>, <LINK REF="STD-Taggart-1988" TYPE="STUDY">Taggart 1988</LINK>), two from Denmark (<LINK REF="STD-Jensen1991" TYPE="STUDY">Jensen1991</LINK>, <LINK REF="STD-Rejnmark-2005" TYPE="STUDY">Rejnmark 2005</LINK>), one from Netherlands (<LINK REF="STD-Herings-1996" TYPE="STUDY">Herings 1996</LINK>), one from Australia (<LINK REF="STD-Cumming-1993" TYPE="STUDY">Cumming 1993</LINK>), and one from the United States (<LINK REF="STD-Barengolts-2001" TYPE="STUDY">Barengolts 2001</LINK>), which was published only as an abstract. While the study from the United States did not declare sponsorship, it can be safely assumed that the United States Department of Veterans Affairs was the funding source since it involved population from the Veterans Affairs Health System.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-09-04 18:23:13 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>The risk of bias assessment of included observational studies was carried out using the NOS for cohort (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and case-control studies (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). When considering comparability in NOS, we assessed whether thiazide users and nonusers were matched in the design and/or whether confounders were adjusted in the analysis. One star point was awarded if age was controlled by the study and another point was awarded if one additional factor was controlled.</P>
<P>
<B>Cohort studies</B>
</P>
<P>The median score (the number of stars awarded) was 8 (out of 9) for the 5 unique cohort studies with a range of 4 to 9 points (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Among 6 reports of cohort studies, 5 had low risk of bias and reached 8 or more star points (<LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK>, <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK>, <LINK REF="STD-Guo-1998" TYPE="STUDY">Guo 1998</LINK>, <LINK REF="STD-LaCroix-1990" TYPE="STUDY">LaCroix 1990</LINK>, <LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>). One had moderate risk of bias and reached 4 star points (<LINK REF="STD-Feskanich-1997" TYPE="STUDY">Feskanich 1997</LINK>). This study reached fewer star points because being part of the Nurses Health Study, the exposed cohort was drawn from the selected group of individuals (nurses) who are not truly representative of the average women in the community. The ascertainment of exposure and outcome relied upon self-report of the participants. The investigators contended, and we concurred, that accurate reporting of fracture and medication use was expected in the cohort of registered nurses. This was reportedly validated in a sample of 30 cases for which all self reports were confirmed by medical records.</P>
<P>
<B>Case-control studies</B>
</P>
<P>The median score (the number of stars awarded) was 6 (out of 9) for the 15 case-control studies with an overall range of 5 to 8 points (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Seven case-control studies had low risk of bias and reached 7 or more star points. The remaining eight had moderate risk of bias and reached 5 to 6 points.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-09-04 18:46:08 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>The findings are summarized in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> for cohort studies and in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for case-control studies.</P>
<P>Among the cohort studies, one found that use of thiazide diuretic agents was associated with a reduction of approximately one third in the risk of hip fracture (<LINK REF="STD-LaCroix-1990" TYPE="STUDY">LaCroix 1990</LINK>); three found that thiazide use was not significantly associated with the risk of hip fracture (<LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK>, <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK>, <LINK REF="STD-Guo-1998" TYPE="STUDY">Guo 1998</LINK>); two found both ways depending on which group was used in final analyses (<LINK REF="STD-Feskanich-1997" TYPE="STUDY">Feskanich 1997</LINK>, <LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>).  In the cohort of <LINK REF="STD-Feskanich-1997" TYPE="STUDY">Feskanich 1997</LINK>, no statistically significant association of thiazide use and hip fracture was found (adjusted RR 0.97; 95% CI, 0.82-1.64) when the entire cohort of 83,728 participants was analysed. It should be noted that this cohort, as described above, was part of the Nurses Health Study. The age of enrolment in the cohort began at 35. The prevalence of osteoporotic hip fracture is very rare in premenopausal women. When analysis was confined only to postmenopausal women from this cohort, thiazide use was associated with reduced risk of hip fracture (adjusted RR 0.69; 95% CI, 0.48-0.99). We chose to use the data on postmenopausal women for our pooled analyses (see below) to be consistent with the study population of other cohort studies. In the cohort of <LINK REF="STD-Schoofs-2003" TYPE="STUDY">Schoofs 2003</LINK>, no beneficial association of thiazide use and the risk of hip fracture was found (adjusted RR 0.71; 95% CI, 0.47-1.06) when the data from the entire cohort, where thiazide use was defined as any current use, was analysed. However, a statistically significant association of thiazide use and reduction of the risk of hip fracture was detected (adjusted RR 0.46; 95% CI, 0.21-0.96) when the analyses was confined to the participants who had been on thiazide use for at least a year. We chose to use the data of the entire cohort defining thiazide use as any current use to be consistent with the data from the rest of the cohort studies. The investigators of all cohort studies attempted to control and adjust for potential confounding variables. Various covariates and potential confounding factors adjusted in each cohort study are shown in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>.</P>
<P>As discussed under description of studies, two cohort studies involved the same cohort. When conducting our meta-analysis, we included the data from <LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK> only because it is primarily focused on association between thiazide use and hip fracture while the focus of <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK> was multiple risk factors for hip fracture, thiazide use being one of them.</P>
<P>Among the case-control studies, seven demonstrated statistically significant association between thiazide use and reduction of the risk of hip fracture (<LINK REF="STD-Barengolts-2001" TYPE="STUDY">Barengolts 2001</LINK>, <LINK REF="STD-Felson-1991" TYPE="STUDY">Felson 1991</LINK>, <LINK REF="STD-Herings-1996" TYPE="STUDY">Herings 1996</LINK>, <LINK REF="STD-Paganini_x002d_Hill-1981" TYPE="STUDY">Paganini-Hill 1981</LINK>, <LINK REF="STD-Rashiq-1986" TYPE="STUDY">Rashiq 1986</LINK>, <LINK REF="STD-Ray-1989" TYPE="STUDY">Ray 1989</LINK>, <LINK REF="STD-Wang-2001" TYPE="STUDY">Wang 2001</LINK>). Eight studies showed no such association (<LINK REF="STD-Cumming-1993" TYPE="STUDY">Cumming 1993</LINK>, <LINK REF="STD-Grisso-1994" TYPE="STUDY">Grisso 1994</LINK>, <LINK REF="STD-Heidrich-1991" TYPE="STUDY">Heidrich 1991</LINK>, <LINK REF="STD-Jensen1991" TYPE="STUDY">Jensen1991</LINK>, <LINK REF="STD-Rejnmark-2005" TYPE="STUDY">Rejnmark 2005</LINK>, <LINK REF="STD-Stevens-1989" TYPE="STUDY">Stevens 1989</LINK>, <LINK REF="STD-Taggart-1988" TYPE="STUDY">Taggart 1988</LINK>, <LINK REF="STD-Weiland-1997" TYPE="STUDY">Weiland 1997</LINK>). As in cohort studies, investigators of case-control studies also attempted to control and adjust for potential confounding variables. Various covariates and potential confounding factors adjusted in each case-control study are shown in <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>.</P>
<P>Meta-analysis of 5 cohort studies (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) showed that thiazide use was associated with a reduction of risk of hip fracture by 24% (pooled RR 0.76; 95% CI 0.64-0.89; p = 0.0009).  Fixed effect model was used in this analysis because no significant heterogeneity among studies was found (p = 0.57, <I>I<SUP>2</SUP>
</I> = 0). Including <LINK REF="STD-Cummings-1995" TYPE="STUDY">Cummings 1995</LINK> in meta-analysis instead of <LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK> (two studies from identical cohort; see above under <LINK TAG="STUDY_DESCRIPTION" TYPE="SECTION">Description of studies</LINK>) found almost identical results (pooled RR 0.75; 95% CI 0.63-0.89; p = 0.0010; p for heterogeneity = 0.61, <I>I<SUP>2</SUP>
</I> = 0).</P>
<P>Forest plot of meta-analysis of 15 case-control studies is shown in <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. We chose not to show pooled summary statistics in the forest plot because it could be misleading in the presence of high degree of heterogeneity (Tau<SUP>2</SUP> = 0.03, I<SUP>2 </SUP>= 62%, p = 0.0008). Clinical diversity such as variations in study location, study setting, age, gender, dosage of thiazide and duration of thiazide use may have contributed to heterogeneity. Adjustment for potential confounding covariates were done in case-control studies but each of them was not adjusted for precisely the same covariates and not conducted under similar conditions. While the investigators of case-control studies made attempts for adjustment of confounding factors to the best they could under given circumstances of each study, several potential risk factors were not assessed in all studies. For example, exposure to sunlight, vitamin D intake and thyroid hormone therapy were not assessed in <LINK REF="STD-Grisso-1994" TYPE="STUDY">Grisso 1994</LINK>. Calcium consumption could not be assessed in most studies. Obese individuals are expected to have higher rates of hypertension (hence thiazide use), yet increased weight is also predictive of lower rates of fractures. However, BMI was not adjusted in all case-control studies. Further, residual confounding by factors that could not be ascertained by chart abstraction, such as strength, balance, endurance, mobility and many other factors, may have occurred in some studies. Each of these factors could have contributed to clinical heterogeneity among case-control studies. It is noteworthy that while the largest case-control study (<LINK REF="STD-Rejnmark-2005" TYPE="STUDY">Rejnmark 2005</LINK>) showed no statically significant association between current use of thiazides and the risk of hip fracture overall (adjusted OR=1.02; 95% CI, 0.96 - 1.08), stratification by defined daily dosages showed dose-response relationship with statistically significant reduction of the risk of hip fracture in the subgroups of higher defined daily dosages. In an attempt to identify the source of heterogeneity, we performed subgroup analyses by geographic regions (North American Sudies and European Studies). Heterogeneity continued to exist in each subgroup (Tau<SUP>2</SUP> = 0.03, p=0.06, <I>I<SUP>2</SUP>
</I> = 51% for North American subgroup; Tau<SUP>2</SUP> = 0.07, p = 0.01, <I>I<SUP>2</SUP>
</I> = 63% for European subgroup) indicating that the source of heterogeneity was more than variation in study location. The small number of studies in the cohort group and differences in the characteristics among the case-control studies precluded the use of meta-regression, a technique that can be used to investigate heterogeneity.</P>
<P>We assessed the publication bias within the included studies using funnel plots. The funnel plot for cohort studies (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>) was not asymmetrical but a small study effect may be difficult to spot among only five studies. The funnel plot for case-control studies (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) was somewhat asymmetrical. This could be due to a relative lack of studies with odds ratio of greater than 1 or differences in methodological quality of smaller studies.</P>
<P>Given differences in baseline risk of hip fractures, we intended to stratify subgroups and analyses performed based on gender. The percentages of females in each included study are shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>. Approximate percentages of females were 86% in cohort studies and 67% in case-control studies. We were unable to perform such subgroup analysis because only few studies reported separate data for each gender. We also intended to perform subgroup analysis based on length of thiazide use but we were unable to do so since few studies reported stratified data for different duration of thiazide use.</P>
<P>
<B>GRADE assessment of total body of evidence</B>
</P>
<P>The evidence from cohort studies showed that thiazide diuretic use was associated with reduction of the risk of hip fracture (RR = 0.76; 95% CI: 0.64, 0.89). Quality of evidence, measured using the criteria of GRADE Working Group grades of evidence, is low because the result was relied solely on observational studies with low to moderate risk of bias (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>The evidence from case-control studies showed that it is indeterminate to conclude whether thiazide diuretic use was associated with reduction of the risk of hip fracture or not. Heterogeneity is high; hence we decided not to report summary statistics of results from case control studies. Quality of evidence, measured using the criteria of GRADE Working Group grades of evidence, is very low (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-09-04 18:31:36 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>Hip fracture is associated with significant morbidity and mortality in older adults. In the year 2000 there were an estimated 9.0 million osteoporotic fractures worldwide, of which 1.6 million were at the hip (<LINK REF="REF-Johnell-2006" TYPE="REFERENCE">Johnell 2006</LINK>). The greatest number of hip fractures was in Europe, followed by the Western Pacific region, the Americas, and southeast Asia. The epidemiologic projections estimate that, this worldwide annual number will rise to 6.26 million by the year 2050 (<LINK REF="REF-Kannus-1996" TYPE="REFERENCE">Kannus 1996</LINK>). While the aging of the world's population contributes to this rise in great part, the age-specific incidence rates of hip fractures have also increased during the recent decades in many parts of the world. The aim of this review was to examine the possible association between thiazide use and the risk of hip fracture. This review includes data from 21 observational studies. We found that current thiazide use was associated with statistically significant reduction of the risk of hip fracture, and could potentially reduce the incidence of hip fracture by approximately 24%. Our findings are consistent with the results of an earlier meta-analysis of 13 observational studies (<LINK REF="STD-Jones-1995" TYPE="STUDY">Jones 1995</LINK>) where current thiazide users were found to have approximately 18% reduction in risk of hip fracture, and a more recent meta-analysis of 19 observational studies (<LINK REF="STD-Wiens-2006" TYPE="STUDY">Wiens 2006</LINK>) where thiazide use was associated with approximately 17% reduction in risk of hip fracture. <LINK REF="STD-Wiens-2006" TYPE="STUDY">Wiens 2006</LINK> analysed cohort studies and case-control studies together but in this review we analysed them separately.</P>
<P>While several medications such as calcium supplements, estrogen, raloxifene, bisphosphonates and zoledronic acid are available in contemporary treatment of osteoporosis, not all medications were shown to reduce the risk of hip fracture. Their adverse effects may also be limiting factors when used for prevention of hip fracture. Many individuals with high risk for hip fracture cannot take any of these medicines due to adverse reactions or contraindications. The potential effectiveness of thiazides in preventing hip fracture could be an alternative option to be considered under such circumstances.</P>
<P>The biological plausibility of the association of thiazides with a lower incidence of hip fracture has been described for several decades. Thiazide use has been related to higher bone mineral density in several observational studies and a few randomized controlled trials as described under the Background section. In addition to their effect on lowering urinary calcium excretion (<LINK REF="REF-Lamberg-1959" TYPE="REFERENCE">Lamberg 1959</LINK>, <LINK REF="REF-Middler-1973" TYPE="REFERENCE">Middler 1973</LINK>), additional mechanisms were also proposed. Thiazides increase intestinal calcium absorption (<LINK REF="REF-Caldwell-1971" TYPE="REFERENCE">Caldwell 1971</LINK>, <LINK REF="REF-Jorgensen-1974" TYPE="REFERENCE">Jorgensen 1974</LINK>, <LINK REF="REF-Zerwekh-1980" TYPE="REFERENCE">Zerwekh 1980</LINK>) and skeletal retention of calcium (<LINK REF="REF-Caldwell-1971" TYPE="REFERENCE">Caldwell 1971</LINK>). Thiazide treatment in some patients is capable of changing a negative calcium balance into a positive direction (<LINK REF="REF-Harrison-1968" TYPE="REFERENCE">Harrison 1968</LINK>). Thiazides may potentiate the renal action of parathyroid hormone, resulting in retention of calcium and partial suppression of parathyroid hormone secretion (<LINK REF="REF-Middler-1973" TYPE="REFERENCE">Middler 1973</LINK>). It has also been suggested that thiazides may stimulate parathyroid glands (<LINK REF="REF-Paloyan-1969" TYPE="REFERENCE">Paloyan 1969</LINK>, <LINK REF="REF-Pickleman-1969" TYPE="REFERENCE">Pickleman 1969</LINK>). One of the properties of thiazides is inhibition of carbonic anhydrase enzyme. The carbonic anhydrase inhibitors are known to inhibit osteoclastic bone resorption in vivo and in vitro in other species (<LINK REF="REF-Pierce-1991" TYPE="REFERENCE">Pierce 1991</LINK>), so it is biologically plausible that thiazides could reduce bone resorption in humans.</P>
<P>Many antihypertensives can cause postural hypotension, which has long been considered an important cause of falls. Receiving hydrochlorothiazide was associated with the highest prevalence of postural hypotension in elderly veterans (<LINK REF="REF-Poon-2005" TYPE="REFERENCE">Poon 2005</LINK>) but the rates of falls among these subjects were not collected in this study. <LINK REF="STD-Cauley-1993" TYPE="STUDY">Cauley 1993</LINK> found that thiazide diuretics had no effect on the risk of falls in older women. Many studies have found no association between falls and antihypertensives (<LINK REF="STD-Cumming-1998" TYPE="STUDY">Cumming 1998</LINK>). Falls were recorded as a potential adverse effect in the Systolic Hypertension in the Elderly Program (SHEP), where chlorthalidone was used as the primary antihypertensive agent. The rates of falls were the same in the treated and placebo groups (<LINK REF="REF-Curb-1993" TYPE="REFERENCE">Curb 1993</LINK>). A systematic review and meta-analysis of drug and falls (<LINK REF="REF-Leipzig-1999" TYPE="REFERENCE">Leipzig 1999</LINK>) showed no statistically significant association between thiazide use and falls. Another meta-analysis (<LINK REF="REF-Woolcott-2009" TYPE="REFERENCE">Woolcott 2009</LINK>) showed no statistically significant association of diuretics and falls although no separate data was available for only thiazides. All these findings were based on observational data and no data from randomized controlled trials were available. A population based case-control study (<LINK REF="REF-Gribbin-2010" TYPE="REFERENCE">Gribbin 2010</LINK>), which was published after these two meta-analyses, found that current prescribing of thiazides was associated with an increased risk of falling and that this was strongest in the first 3 weeks. An updated systematic review and meta-analysis is warranted to explore whether withholding thiazide diuretics in older adults because of the concerns related to risk of falls is justified.</P>
<P>Our review has several limitations. Included primary studies in our review consist of only observational studies and no randomized trials. Associations detected in observational studies could be due to the possibility that the association was caused by a third factor linked to both exposure/intervention and outcome. Statistically significant associations found in observational studies could be subject to <I>post hoc ergo propter hoc</I> and <I>cum hoc ergo propter hoc</I> fallacies so caution should be exercised against overinterpretation of the summary statistics. While heterogeneity was very low among the cohort studies, it was fairly high among the case-control studies. Potential sources of clinical heterogeneity among case-control studies and the role of confounding covariates left unadjusted are discussed under <LINK TAG="RESULTS" TYPE="SECTION">Results</LINK> above. There are potentially unpublished case-control studies with effect sizes of odds ratios greater than 1 indicated by funnel plot. Validity can be affected by losses to follow-up in cohort studies but we suspect that it is unlikely to introduce bias to our results because only small proportion were lost to follow-up in most included studies. Assessment of thiazide use only at baseline in some cohort studies could have precluded its introduction at a later date affecting accuracy of ascertainment of exposure. Recall bias could be another potential limitation of case-control studies but most of the included studies used medical records or pharmacy database to ascertain thiazide use so it may not be much of a threat to the validity of our results. Detection bias could occur when cases and controls are not identified independently of the exposure in case control studies. Case-control studies could be susceptible to the healthy volunteer effect since previous fracture is a strong predictor of fracture and those who do not go to see the doctors for fractures are the same people as those who do not see their doctors for hypertension. Finally, we were unable to determine the minimum duration of thiazide use necessary to achieve the preventive effect for hip fractures in our pooled analyses of included studies because only few included studies had information on duration of thiazide use. We were also unable to determine the dose response relationship of such association because most included studies did not address this issue.</P>
<P>The limitations of contemporary therapy for osteoporosis make thiazides attractive as an alternative option. Many older adults who are at high risk for hip fracture also have hypertension as a coexisting medical condition. Use of thiazides has a convincing effect on stroke prevention in hypertensive individuals so using the same medication for reduction of risk of hip fracture would be an appropriate choice. However, potential adverse effects of thiazides such as hypokalaemia, hyponatraemia, precipitation of gout, volume depletion and orthostatic hypotension should be weighed in clinical decision making.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-09-04 18:31:59 -0500" MODIFIED_BY="Ciprian D Jauca">
<IMPLICATIONS_PRACTICE MODIFIED="2011-09-04 18:31:59 -0500" MODIFIED_BY="James M Wright">
<P>Thiazides appear to reduce the risk of hip fracture based on observational studies. Randomized controlled trials are needed to confirm these findings. Until randomised control trials assessing the effect of thiazides on incidence of hip fracture are conducted and the results from such trial are available, physicians and clinical practice guideline writers should consider this potential advantageous effect of thiazides over other antihypertensives in treating hypertension particularly in individuals with high probability of hip fracture.   </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-08-31 18:59:04 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>Future research is very likely to have an important impact on our confidence in the estimate of the effect and is likely to change the estimate, based on our GRADE assessment of the total body of evidence. Rigorously assessing the benefits of thiazides in preventing osteoporotic hip fractures in clinical trials is crucial to selecting appropriate antihypertensive agents in the population with high probability of hip fracture.  There is a need to conduct large scale randomized control trials to assess the efficacy of thiazides in prevention of hip fracture, and their relative safety in individuals without a history of hypertension. Such trials should also determine the minimum dose and duration of thiazide use necessary to achieve effective reduction of the risk of hip fracture. Hip fractures can have serious morbidity and mortality consequences. After sustaining a hip fracture, a person may be unable to perform activities of daily living and/or unable to live independently.  Development of serious complications such as pneumonia or venous thromboembolism could lead to death.  Adverse effects of available medications for treatment of osteoporosis and their cost can prohibit individuals with high probability of hip fracture from receiving appropriate therapy, and thiazides could be an alternative option for such individuals. Because of the serious nature of hip fracture, worldwide expansion of the population prone to risk fracture and limitations of current treatment of osteoporosis, such trials assessing the efficacy of thiazides should be given a priority. The pharmaceutical industry would have very little commercial incentive to fund such trials, given that the patents of thiazide diuretics have long run out. We call upon public and private non-profit organizations around the globe to give priority in funding such trials to evaluate this inexpensive and potentially effective therapeutic option for prevention of hip fracture in older adults.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-08-31 19:00:07 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>We would like to thank Ciprian Jauca, Managing Editor, Cochrane Hypertension Group for his valuable support. Furthermore, we would like to thank Dr. Doug Altman, Cochrane Statistical Methods Group and Dr. Tianjing Li, Cochrane Eye and Vision Group for their assistance with data analysis. Finally, we would like to thank Dr. Benji Heran, Cochrane Hypertension Group for his assistance with literature search.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-08-31 19:00:39 -0500" MODIFIED_BY="Ciprian D Jauca">
<P>None known. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-17 17:10:41 -0600" MODIFIED_BY="[Empty name]">
<P>K. Aung contributed to all parts of the review.</P>
<P>T. Htay contributed to background, identification of studies, assessment of risk of bias (methodological quality) of included studies, data extraction, discussion, and conclusions.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-08-31 16:51:49 -0500" MODIFIED_BY="James M Wright">
<STUDIES MODIFIED="2011-03-04 18:53:13 -0600" MODIFIED_BY="James M Wright">
<INCLUDED_STUDIES MODIFIED="2011-03-04 18:53:13 -0600" MODIFIED_BY="James M Wright">
<STUDY DATA_SOURCE="PUB" ID="STD-Barengolts-2001" MODIFIED="2009-12-10 19:34:35 -0600" MODIFIED_BY="[Empty name]" NAME="Barengolts 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-12-10 19:34:32 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barengolts E, Karanouh D, Kolodny L, Kukreja S</AU>
<TI>Risk factors for hip fracture in predominantly African American Veteran Male Population</TI>
<SO>J Bone Miner Res</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>Suppl</NO>
<PG>S170</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cauley-1993" MODIFIED="2009-06-03 16:00:33 -0500" MODIFIED_BY="[Empty name]" NAME="Cauley 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-06-03 16:00:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cauley J A, Cummings S R, Seeley D G, Black D, Browner W, Kuller L H, et al</AU>
<TI>Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>118</VL>
<NO>9</NO>
<PG>666-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cumming-1993" MODIFIED="2009-06-03 15:27:00 -0500" MODIFIED_BY="[Empty name]" NAME="Cumming 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-06-03 15:27:00 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cumming R G, Klineberg R J</AU>
<TI>Psychotropics, thiazide diuretics and hip fractures in the elderly</TI>
<SO>Med J Aust</SO>
<YR>1993</YR>
<VL>158</VL>
<NO>6</NO>
<PG>414-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cummings-1995" MODIFIED="2009-11-05 18:06:13 -0600" MODIFIED_BY="[Empty name]" NAME="Cummings 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-11-05 18:06:13 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Mar 23Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research GroupCummings, S R&lt;br&gt;Nevitt, M C&lt;br&gt;Browner, W S&lt;br&gt;Stone, K&lt;br&gt;Fox, K M&lt;br&gt;Ensrud, K E&lt;br&gt;Cauley, J&lt;br&gt;Black, D&lt;br&gt;Vogt, T M&lt;br&gt;1-RO1-AG05407/AG/NIA NIH HHS/United States&lt;br&gt;1-RO1-AR35582/AR/NIAMS NIH HHS/United States&lt;br&gt;5-RO1-AG05394/AG/NIA NIH HHS/United States&lt;br&gt;etc.&lt;br&gt;Multicenter Study&lt;br&gt;Research Support, U.S. Gov't, P.H.S.&lt;br&gt;United states&lt;br&gt;The New England journal of medicine&lt;br&gt;N Engl J Med. 1995 Mar 23;332(12):767-73.&lt;/p&gt;" NOTES_MODIFIED="2009-11-05 18:06:13 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cummings S R, Nevitt M C, Browner W S, Stone K, Fox K M, Ensrud K E, et al</AU>
<TI>Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>332</VL>
<NO>12</NO>
<PG>767-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felson-1991" MODIFIED="2009-07-23 10:23:16 -0500" MODIFIED_BY="[Empty name]" NAME="Felson 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-23 10:23:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felson D T, Sloutskis D, Anderson J J, Anthony J M, Kiel D P</AU>
<TI>Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<NO>3</NO>
<PG>370-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feskanich-1997" MODIFIED="2009-05-21 13:51:54 -0500" MODIFIED_BY="[Empty name]" NAME="Feskanich 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-05-21 13:51:54 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feskanich D, Willett W C, Stampfer M J, Colditz G A</AU>
<TI>A prospective study of thiazide use and fractures in women</TI>
<SO>Osteoporos Int</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>1</NO>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grisso-1994" MODIFIED="2009-07-24 14:02:41 -0500" MODIFIED_BY="[Empty name]" NAME="Grisso 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-07-24 14:02:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grisso JA, Kelsey JL, Strom BL, O'Brien LA, Maislin G, LaPann K, Samelson L, Hoffman S</AU>
<TI>Risk factors for hip fracture in black women. The Northeast Hip Fracture Study Group</TI>
<SO>N Engl J Med</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>22</NO>
<PG>1555-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-1998" MODIFIED="2009-05-21 10:51:14 -0500" MODIFIED_BY="[Empty name]" NAME="Guo 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-05-21 10:51:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo Z, Wills P, Viitanen M, Fastbom J, Winblad B</AU>
<TI>Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 years old: a community-based prospective study</TI>
<SO>Am J Epidemiol</SO>
<YR>1998</YR>
<VL>148</VL>
<NO>9</NO>
<PG>887-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heidrich-1991" MODIFIED="2009-07-23 10:13:26 -0500" MODIFIED_BY="[Empty name]" NAME="Heidrich 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-23 10:13:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heidrich FE, Stergachis A, Gross KM</AU>
<TI>Diuretic drug use and the risk for hip fracture</TI>
<SO>Ann Intern Med</SO>
<YR>1991</YR>
<VL>115</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herings-1996" MODIFIED="2009-06-03 13:47:22 -0500" MODIFIED_BY="[Empty name]" NAME="Herings 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-06-03 13:47:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herings R M, Stricker B H, de Boer A, Bakker A, Sturmans F, Stergachis A</AU>
<TI>Current use of thiazide diuretics and prevention of femur fractures</TI>
<SO>J Clin Epidemiol</SO>
<YR>1996</YR>
<VL>49</VL>
<NO>1</NO>
<PG>115-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen1991" MODIFIED="2009-08-06 12:13:10 -0500" MODIFIED_BY="[Empty name]" NAME="Jensen1991" YEAR="1991">
<REFERENCE MODIFIED="2009-08-06 12:13:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen J, Nielsen LH, Lyhne N, Hallas J, Brosen K, Gram LF</AU>
<TI>Drugs and femoral neck fracture: a case control study</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1991</YR>
<VL>229</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LaCroix-1990" MODIFIED="2009-07-23 10:42:56 -0500" MODIFIED_BY="[Empty name]" NAME="LaCroix 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-07-23 10:42:56 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaCroix A Z, Wienpahl J, White L R, Wallace R B, Scherr P A, George L K, et al</AU>
<TI>Thiazide diuretic agents and the incidence of hip fracture</TI>
<SO>N Engl J Med</SO>
<YR>1990</YR>
<VL>322</VL>
<NO>5</NO>
<PG>286-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paganini_x002d_Hill-1981" MODIFIED="2009-07-23 13:33:16 -0500" MODIFIED_BY="[Empty name]" NAME="Paganini-Hill 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-07-23 13:33:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paganini-Hill A, Rose RK, Gerkins VR, et al</AU>
<TI>Memopausal estrogen therapy and hip fracture</TI>
<SO>Ann Intern Med</SO>
<YR>1981</YR>
<VL>95</VL>
<PG>28-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rashiq-1986" MODIFIED="2009-07-23 12:37:23 -0500" MODIFIED_BY="[Empty name]" NAME="Rashiq 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-07-23 12:37:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rashiq S, Logan R F</AU>
<TI>Role of drugs in fractures of the femoral neck</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1986</YR>
<VL>292</VL>
<NO>6524</NO>
<PG>861-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-1989" MODIFIED="2009-07-23 10:45:05 -0500" MODIFIED_BY="[Empty name]" NAME="Ray 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-07-23 10:45:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray W A, Griffin M R, Downey W, Melton L J 3rd</AU>
<TI>Long-term use of thiazide diuretics and risk of hip fracture</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8640</NO>
<PG>687-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rejnmark-2005" MODIFIED="2011-03-04 18:53:13 -0600" MODIFIED_BY="James M Wright" NAME="Rejnmark 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-03-04 18:53:13 -0600" MODIFIED_BY="James M Wright" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rejnmark L, Vestergaard P, Mosekilde L</AU>
<TI>Reduced fracture risk in users of thiazide diuretics</TI>
<SO>Calcif Tissue Int</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>3</NO>
<PG>167-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoofs-2003" MODIFIED="2009-05-21 10:33:58 -0500" MODIFIED_BY="[Empty name]" NAME="Schoofs 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-21 10:33:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoofs MW, van der Klift M, Hofman A, de Laet CE, Herings RM, Stijnen T, Pols HA, Stricker BH</AU>
<TI>Thiazide diuretics and the risk for hip fracture</TI>
<SO>Ann Intern Med</SO>
<YR>2003</YR>
<VL>139</VL>
<PG>476-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-1989" MODIFIED="2009-07-23 14:16:03 -0500" MODIFIED_BY="[Empty name]" NAME="Stevens 1989" YEAR="1989">
<REFERENCE MODIFIED="2009-07-23 14:16:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens A, Murlow C</AU>
<TI>Drugs affecting postural stability and other risk factors in hip fracture epidemic - case control study</TI>
<SO>Community Med</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taggart-1988" MODIFIED="2009-07-24 12:36:11 -0500" MODIFIED_BY="[Empty name]" NAME="Taggart 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-07-24 12:36:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taggart HM</AU>
<TI>Do drugs affect the risk of hip fracture in elderly women?</TI>
<SO>J Am Geriatr Soc</SO>
<YR>1988</YR>
<VL>36</VL>
<NO>11</NO>
<PG>1006-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2001" MODIFIED="2009-12-10 19:31:22 -0600" MODIFIED_BY="[Empty name]" NAME="Wang 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-12-10 19:31:22 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DecZolpidem use and hip fractures in older peopleWang, P S&lt;br&gt;Bohn, R L&lt;br&gt;Glynn, R J&lt;br&gt;Mogun, H&lt;br&gt;Avorn, J&lt;br&gt;R01 DA100014-01/DA/NIDA NIH HHS/United States&lt;br&gt;R03-AG 18395/AG/NIA NIH HHS/United States&lt;br&gt;Comparative Study&lt;br&gt;Research Support, U.S. Gov't, P.H.S.&lt;br&gt;United States&lt;br&gt;Journal of the American Geriatrics Society&lt;br&gt;J Am Geriatr Soc. 2001 Dec;49(12):1685-90.eng&lt;/p&gt;" NOTES_MODIFIED="2009-12-10 19:31:22 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang P S, Bohn R L, Glynn R J, Mogun H, Avorn J</AU>
<TI>Zolpidem use and hip fractures in older people</TI>
<SO>J Am Geriatr Soc</SO>
<YR>2001</YR>
<VL>49</VL>
<NO>12</NO>
<PG>1685-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiland-1997" MODIFIED="2009-07-23 13:02:47 -0500" MODIFIED_BY="[Empty name]" NAME="Weiland 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-07-23 13:02:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weiland SK, Ruckmann A, Keil U, Lewis M, Dennler H, Welzel D</AU>
<TI>Thiazide diuretics and risk of hip fractures among 70-79 year old women treated for hypertension</TI>
<SO>European Journal of Public Health</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>3</NO>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-22 00:04:33 -0600" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Adland_x002d_Davenport-1985" MODIFIED="2009-07-24 15:34:19 -0500" MODIFIED_BY="[Empty name]" NAME="Adland-Davenport 1985" YEAR="1985">
<REFERENCE MODIFIED="2009-07-23 13:00:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adland-Davenport P, McKenzie M W, Notelovitz M, McKenzie L C, Pendergast J F</AU>
<TI>Thiazide diuretics and bone mineral content in postmenopausal women</TI>
<SO>Am J Obstet Gynecol</SO>
<YR>1985</YR>
<VL>152</VL>
<NO>6 Pt 1</NO>
<PG>630-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-2004" MODIFIED="2009-07-29 09:42:23 -0500" MODIFIED_BY="[Empty name]" NAME="Allen 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-07-23 13:28:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen G</AU>
<TI>Patients' questions about orthopedic surgery; surgical errors; thiazide diuretics; iodophor-impregnated drapes</TI>
<SO>AORN Journal</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>2</NO>
<PG>498-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2003" MODIFIED="2009-07-29 15:30:38 -0500" MODIFIED_BY="[Empty name]" NAME="Anonymous 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-07-29 15:30:38 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Summaries for patients. Thiazide diuretics and hip fracture risk</TI>
<SO>Annals of internal medicine</SO>
<YR>2003</YR>
<VL>139</VL>
<NO>6</NO>
<PG>I36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="13679346"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anonymous-2004" MODIFIED="2009-08-07 17:05:28 -0500" MODIFIED_BY="[Empty name]" NAME="Anonymous 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-07 17:05:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Thiazide diuretics may protect against hip fracture</TI>
<SO>U.S. Pharmacist</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>1</NO>
<PG>HS31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benetos-2007" MODIFIED="2009-08-27 09:13:17 -0500" MODIFIED_BY="[Empty name]" NAME="Benetos 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-27 09:13:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benetos IS, Babis GC, Zoubos AB, Benetou V, Soucacos PN</AU>
<TI>Factors affecting the risk of hip fractures</TI>
<SO>Injury</SO>
<YR>2007</YR>
<VL>38</VL>
<NO>7</NO>
<PG>735-744</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bolland-2007" MODIFIED="2009-07-29 11:16:11 -0500" MODIFIED_BY="[Empty name]" NAME="Bolland 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-07-29 11:16:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bolland M J, Ames R W, Horne A M, Orr-Walker B J, Gamble G D, Reid I R</AU>
<TI>The effect of treatment with a thiazide diuretic for 4 years on bone density in normal postmenopausal women</TI>
<SO>Osteoporos Int</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>4</NO>
<PG>479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bouwmeester-2004" MODIFIED="2009-08-19 11:55:33 -0500" MODIFIED_BY="[Empty name]" NAME="Bouwmeester 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-19 11:55:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bouwmeester MC</AU>
<TI>Thiazide diuretics and risk of hip fracture</TI>
<SO>Quebec Pharmacie</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>2</NO>
<PG>152</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cumming-1998" MODIFIED="2009-08-27 09:12:16 -0500" MODIFIED_BY="[Empty name]" NAME="Cumming 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-27 09:12:16 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Review article&lt;/p&gt;" NOTES_MODIFIED="2009-08-27 09:12:16 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cumming RG</AU>
<TI>Epidemiology of medication-related falls and fractures in the elderly</TI>
<SO>Drugs and Aging</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>1</NO>
<PG>43-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grisso-1991" MODIFIED="2009-07-24 15:32:29 -0500" MODIFIED_BY="[Empty name]" NAME="Grisso 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-24 15:32:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grisso JA, Kelsey JL, Strom BL, Chiu GY, Maislin G, O'Brien LA, Hoffman S, Kaplan F</AU>
<TI>Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group</TI>
<SO>N Engl J Med</SO>
<YR>1991</YR>
<VL>324</VL>
<NO>19</NO>
<PG>1326-1331</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hale-1984" MODIFIED="2009-07-24 15:57:49 -0500" MODIFIED_BY="[Empty name]" NAME="Hale 1984" YEAR="1984">
<REFERENCE MODIFIED="2009-07-24 15:57:49 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hale WE, Stewart RB, Marks RG</AU>
<TI>Central nervous system symptoms of elderly subjects using antihypertensive drugs</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1984</YR>
<VL>32</VL>
<NO>1</NO>
<PG>5-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="6690577"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jergas-1994" MODIFIED="2009-08-07 16:59:15 -0500" MODIFIED_BY="[Empty name]" NAME="Jergas 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-08-07 16:59:15 -0500" MODIFIED_BY="[Empty name]" NOTES="ger" NOTES_MODIFIED="2009-08-07 16:59:15 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jergas M, Kosow A, Uffmann M, Schmutz G, Bockenforde J B, Gluer C C, et al</AU>
<TI>[The effect of a low-dose hydrochlorothiazide therapy on the bone mineral content of the axial and peripheral skeleton]</TI>
<SO>Dtsch Med Wochenschr</SO>
<YR>1994</YR>
<VL>119</VL>
<NO>48</NO>
<PG>1645-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1995" MODIFIED="2009-08-19 11:41:16 -0500" MODIFIED_BY="[Empty name]" NAME="Jones 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-08-19 11:41:16 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones G, Nguyen T, Sambrook PN, Eisman JA</AU>
<TI>Thiazide diuretics and fractures: can meta-analysis help?</TI>
<SO>J Bone Miner Res J Bone Miner Res</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>106-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LaCroix-2000" MODIFIED="2009-07-29 09:42:49 -0500" MODIFIED_BY="[Empty name]" NAME="LaCroix 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-23 10:10:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE</AU>
<TI>Low-Dose Hydrochlorothiazide and Preservation of Bone Mineral Density in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial</TI>
<SO>Ann Intern Med</SO>
<YR>2000</YR>
<VL>133</VL>
<PG>516-526</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lim-2005" MODIFIED="2010-11-22 00:04:33 -0600" MODIFIED_BY="[Empty name]" NAME="Lim 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-22 00:04:33 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lim LS, Fink HA, Kuskowski MA, Cauley JA, Ensrud KE</AU>
<TI>Diuretic use and bone mineral density in older USA men: the osteoporotic fractures in men (MrOS) study</TI>
<SO>Age and ageing</SO>
<YR>2005</YR>
<VL>34</VL>
<NO>5</NO>
<PG>504-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nguyen-1996" MODIFIED="2009-07-29 09:43:10 -0500" MODIFIED_BY="[Empty name]" NAME="Nguyen 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-07-23 13:31:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN</AU>
<TI>Risk factors for osteoporotic fractures in elderly men</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>144</VL>
<NO>3</NO>
<PG>255-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-1991" MODIFIED="2009-07-29 16:19:12 -0500" MODIFIED_BY="[Empty name]" NAME="Ray 1991" YEAR="1991">
<REFERENCE MODIFIED="2009-07-29 16:19:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray W A</AU>
<TI>Thiazide diuretics and osteoporosis: time for a clinical trial?</TI>
<SO>Ann Intern Med</SO>
<YR>1991</YR>
<VL>115</VL>
<NO>1</NO>
<PG>64-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-2000" MODIFIED="2009-07-29 16:17:45 -0500" MODIFIED_BY="[Empty name]" NAME="Reid 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-07-29 16:17:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid I R, Ames R W, Orr-Walker B J, Clearwater J M, Horne A M, Evans M C, et al</AU>
<TI>Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial</TI>
<SO>Am J Med</SO>
<YR>2000</YR>
<VL>109</VL>
<NO>5</NO>
<PG>362-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sernbo-1987" MODIFIED="2009-08-07 16:57:45 -0500" MODIFIED_BY="[Empty name]" NAME="Sernbo 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-08-07 16:57:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sernbo I, Hansson A, Johnell O</AU>
<TI>Drug consumption in patients with hip fractures compared with controls</TI>
<SO>Comprehensive gerontology. Section A, Clinical and laboratory sciences</SO>
<YR>1987</YR>
<VL>1</VL>
<NO>3</NO>
<PG>93-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="2898976"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sigurdsson-2001" MODIFIED="2009-07-24 17:58:43 -0500" MODIFIED_BY="[Empty name]" NAME="Sigurdsson 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-07-24 17:58:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sigurdsson G, Franzson L</AU>
<TI>Increased bone mineral density in a population-based group of 70-year-old women on thiazide diuretics, independent of parathyroid hormone levels</TI>
<SO>Journal of internal medicine</SO>
<YR>2001</YR>
<VL>250</VL>
<NO>1</NO>
<PG>51-6</PG>
<IDENTIFIERS MODIFIED="2009-07-24 17:58:41 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="11454142"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thapa-1993" MODIFIED="2010-11-21 22:35:28 -0600" MODIFIED_BY="[Empty name]" NAME="Thapa 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-08-07 17:03:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thapa PB, Ray WA</AU>
<TI>Can thiazide diuretics be recommended routinely to reduce hip fracture risk?</TI>
<SO>Drugs &amp; aging</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>2</NO>
<PG>99-105</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="PUBMED" VALUE="8477150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-07 17:04:05 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasnich-1983" MODIFIED="2009-07-29 09:43:30 -0500" MODIFIED_BY="[Empty name]" NAME="Wasnich 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-07-23 13:51:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasnich RD, Benfante RJ, Yano K, Heilbrun L, Vogel JM</AU>
<TI>Thiazide effect on the mineral content of bone</TI>
<SO>N Engl J Med</SO>
<YR>1983</YR>
<VL>309</VL>
<PG>344-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasnich-1986" MODIFIED="2009-07-29 09:43:47 -0500" MODIFIED_BY="[Empty name]" NAME="Wasnich 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-07-23 14:00:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasnich RD, Ross PD, Heilbrun LK, Vogel JM, Yano K, Benfante RJ</AU>
<TI>Differential effects of thiazide and estrogen upon bone mineral content and fracture prevalence</TI>
<SO>Obstet Gynecol</SO>
<YR>1986</YR>
<VL>67</VL>
<NO>4</NO>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasnich-1990" MODIFIED="2009-07-29 09:44:06 -0500" MODIFIED_BY="[Empty name]" NAME="Wasnich 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-07-23 13:56:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasnich R, Davis J, Ross P, Vogel J</AU>
<TI>Effect of thiazide on rates of bone mineral loss: a longitudinal study</TI>
<SO>Br Med J</SO>
<YR>1990</YR>
<VL>301</VL>
<NO>6764</NO>
<PG>1303-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiens-2006" MODIFIED="2009-08-19 11:42:12 -0500" MODIFIED_BY="[Empty name]" NAME="Wiens 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-19 11:42:12 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiens M, Etminan M, Gill S S, Takkouche B</AU>
<TI>Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies</TI>
<SO>J Intern Med</SO>
<YR>2006</YR>
<VL>260</VL>
<NO>4</NO>
<PG>350-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-11-21 19:05:05 -0600" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-08-31 16:51:49 -0500" MODIFIED_BY="James M Wright">
<ADDITIONAL_REFERENCES MODIFIED="2011-08-31 16:51:49 -0500" MODIFIED_BY="James M Wright">
<REFERENCE ID="REF-ALLHAT-2000" NAME="ALLHAT 2000" TYPE="JOURNAL_ARTICLE">
<AU>ALLHAT Collaborative Research Group</AU>
<TI>Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</TI>
<SO>JAMA</SO>
<YR>2000</YR>
<VL>283</VL>
<PG>1967-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ALLHAT-2002" NAME="ALLHAT 2002" TYPE="JOURNAL_ARTICLE">
<AU>The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group</AU>
<TI>The Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Anti-hypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>2981-2997</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bauer-1993" NAME="Bauer 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, et al</AU>
<TI>Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>118</VL>
<PG>657-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caldwell-1971" MODIFIED="2010-11-21 13:59:17 -0600" MODIFIED_BY="[Empty name]" NAME="Caldwell 1971" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell JG, Avioli LG, Boisseau C</AU>
<TI>Hydrochlorothiazide and calcium homeostasis in idiopathic hypercalciuria</TI>
<SO>Clin Res</SO>
<YR>1971</YR>
<VL>19</VL>
<PG>676</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cumming-1991" NAME="Cumming 1991" TYPE="JOURNAL_ARTICLE">
<AU>Cumming RG, Miller JP, Kelsey JL, Davis P, Arfken CL, Birge SJ</AU>
<TI>Medications and multiple falls in elderly people: The St. Louis OASIS Study</TI>
<SO>Age aging</SO>
<YR>1991</YR>
<VL>20</VL>
<PG>455-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curb-1993" MODIFIED="2010-11-22 00:05:13 -0600" MODIFIED_BY="[Empty name]" NAME="Curb 1993" TYPE="JOURNAL_ARTICLE">
<AU>Curb JD, Applegate WB, Vogt TM</AU>
<TI>Antihypertensive therapy and falls and fractures in the Systolic Hypertension in the ElderlyProgram [abstract]</TI>
<SO>J Am Geriatr Soc</SO>
<YR>1993</YR>
<VL>41</VL>
<NO>Suppl. 1</NO>
<PG>SA15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Control Clin Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glynn-1995" NAME="Glynn 1995" TYPE="JOURNAL_ARTICLE">
<AU>Glynn NW, Meilahn EN, Charron M, Anderson SJ, Kuller LH, Cauley JA</AU>
<TI>Determinants of bone mineral density in older men</TI>
<SO>J Bone Miner Res</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>1769-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gribbin-2010" MODIFIED="2011-07-24 00:24:16 -0500" MODIFIED_BY="[Empty name]" NAME="Gribbin 2010" TYPE="JOURNAL_ARTICLE">
<AU>Gribbin J, Hubbard R, Gladman JR, Smith C, Lewis S</AU>
<TI>Risk of falls associated with antihypertensive medication: population-based case-control study</TI>
<SO>Age Ageing</SO>
<YR>2010</YR>
<VL>39</VL>
<NO>5</NO>
<PG>592-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansson-1999" NAME="Hansson 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hansson L, Lindholm LH, Niskanen L, et al 611-616</AU>
<TI>Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<PG>611-616</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harrison-1968" MODIFIED="2010-11-22 00:05:34 -0600" MODIFIED_BY="[Empty name]" NAME="Harrison 1968" TYPE="JOURNAL_ARTICLE">
<AU>Harrison AR, Rose GA</AU>
<TI>The effect of bendrofluazide on urinary and faecal calcium and phosphorus</TI>
<SO>Clinical Science</SO>
<YR>1968</YR>
<VL>34</VL>
<PG>343</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-11-18 11:25:46 -0600" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnell-2006" MODIFIED="2010-11-21 12:03:38 -0600" MODIFIED_BY="[Empty name]" NAME="Johnell 2006" TYPE="JOURNAL_ARTICLE">
<AU>Johnell O, Kanis JA</AU>
<TI>An estimate of the worldwide prevalence and disability associated with osteoporotic fractures</TI>
<SO>Osteoporos Int</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>12</NO>
<PG>1726-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorgensen-1974" MODIFIED="2010-11-21 14:07:24 -0600" MODIFIED_BY="[Empty name]" NAME="Jorgensen 1974" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen FS, Transbol I</AU>
<TI>The effect of bendroflumethiazide on the intestinal absorption of calcium in normocalcaemic renal stone formers and in hyperparathyroidism</TI>
<SO>Acta Med Scand</SO>
<YR>1974</YR>
<VL>195</VL>
<NO>1-2</NO>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kannus-1996" MODIFIED="2010-11-21 12:24:35 -0600" MODIFIED_BY="[Empty name]" NAME="Kannus 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kannus P, Parkkari J, Sievänen H, Heinonen A, Vuori I, Järvinen M</AU>
<TI>Epidemiology of hip fractures</TI>
<SO>Bone</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>1 Suppl</NO>
<PG>57S-63S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lamberg-1959" NAME="Lamberg 1959" TYPE="JOURNAL_ARTICLE">
<AU>Lamberg B-A, Kuhlback B</AU>
<TI>Effect of chlorthiazide and hydrochlorothiazide on excretion of calcium in urine</TI>
<SO>Scan J Clin Lab Invest</SO>
<YR>1959</YR>
<VL>11</VL>
<PG>351-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leipzig-1999" MODIFIED="2011-07-24 00:31:23 -0500" MODIFIED_BY="[Empty name]" NAME="Leipzig 1999" TYPE="JOURNAL_ARTICLE">
<AU>Leipzig RM, Cumming RG, Tinetti ME</AU>
<TI>Drugs and falls in older people: a systematic review and meta-analysis: II. Cardiac and analgesic drugs</TI>
<SO>J Am Geriatr Soc</SO>
<YR>1999</YR>
<VL>47</VL>
<NO>1</NO>
<PG>40-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" NAME="Mantel 1959" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from retrospective studies of disease</TI>
<SO>J Natl Cancer Inst</SO>
<YR>1959</YR>
<VL>22</VL>
<PG>719-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Middler-1973" NAME="Middler 1973" TYPE="JOURNAL_ARTICLE">
<AU>Middler S, Pak CY, Murad F, Bartter FC</AU>
<TI>Thiazide diuretics and calcium metabolism</TI>
<SO>Metabolism</SO>
<YR>1973</YR>
<VL>22</VL>
<PG>139-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morton-1994" NAME="Morton 1994" TYPE="JOURNAL_ARTICLE">
<AU>Morton DJ, Barrett-Connor EL, Edelstein SL</AU>
<TI>Thiazides and bone mineral density in elderly men and women</TI>
<SO>Am J Epidemiol</SO>
<YR>1994</YR>
<VL>139</VL>
<PG>1107-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MRC-1985" NAME="MRC 1985" TYPE="JOURNAL_ARTICLE">
<AU>Medical Research Council Working Party</AU>
<TI>MRC trial of treatment of mild hypertension: principal results</TI>
<SO>Br Med J (Clin Res Ed)</SO>
<YR>1985</YR>
<VL>291</VL>
<PG>97-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myers-1978" NAME="Myers 1978" TYPE="JOURNAL_ARTICLE">
<AU>Myers MG, Kearns PM, Kennedy DS, Fisher RH</AU>
<TI>Postural hypotension and diuretic therapy in the elderly</TI>
<SO>Can Med Assoc J</SO>
<YR>1978</YR>
<VL>119</VL>
<PG>581-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nassim-1965" MODIFIED="2010-11-17 17:14:08 -0600" MODIFIED_BY="[Empty name]" NAME="Nassim 1965" TYPE="JOURNAL_ARTICLE">
<AU>Nassim JR, Higgins BA</AU>
<TI>Control of Idiopathic Hypercalciuria</TI>
<SO>Br Med J</SO>
<YR>1965</YR>
<VL>1</VL>
<PG>675-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paloyan-1969" MODIFIED="2010-11-22 00:05:56 -0600" MODIFIED_BY="[Empty name]" NAME="Paloyan 1969" TYPE="JOURNAL_ARTICLE">
<AU>Paloyan E, Forland M, Pickleman JR</AU>
<TI>Hyperparathyroidism co-existing with hypertension and prolonged thiazide administration.</TI>
<SO>JAMA</SO>
<YR>1969</YR>
<VL>210</VL>
<PG>1243</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pickleman-1969" MODIFIED="2010-11-21 14:57:09 -0600" MODIFIED_BY="[Empty name]" NAME="Pickleman 1969" TYPE="JOURNAL_ARTICLE">
<AU>Pickleman JR, Straus FH, Forland M, Paloyan E</AU>
<TI>Thiazide-induced parathyroid stimulation</TI>
<SO>Metabolism</SO>
<YR>1969</YR>
<VL>18</VL>
<PG>867</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pierce-1991" MODIFIED="2010-11-21 14:36:44 -0600" MODIFIED_BY="[Empty name]" NAME="Pierce 1991" TYPE="JOURNAL_ARTICLE">
<AU>Pierce WM, Nardin GF, Fuqua MF, Sabah-Maren E, Stern SH</AU>
<TI>Effect of Chronic Carbonic Anhydrase InhibitorTherapy on Bone Mineral Density in White Women</TI>
<SO>J Bone Miner Res</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>4</NO>
<PG>347-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poon-2005" MODIFIED="2011-07-24 00:17:36 -0500" MODIFIED_BY="[Empty name]" NAME="Poon 2005" TYPE="JOURNAL_ARTICLE">
<AU>Poon IO, Braun U</AU>
<TI>High prevalence of orthostatic hypotension and its correlation with potentially causative medications among elderly veterans</TI>
<SO>J Clin Pharm Ther</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>2</NO>
<PG>173-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Psaty-2003" MODIFIED="2011-08-31 15:37:11 -0500" MODIFIED_BY="James M Wright" NAME="Psaty 2003" TYPE="JOURNAL_ARTICLE">
<AU>Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS</AU>
<TI>Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>2534-2544</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reeves-1999" MODIFIED="2011-07-24 18:00:39 -0500" MODIFIED_BY="[Empty name]" NAME="Reeves 1999" TYPE="CONFERENCE_PROC">
<AU>Reeves B, Maclehose R, Harvey I, Sheldon T, Russell I, Black A</AU>
<TI>Internal validity of estimates of effectiveness from non-randomised studies</TI>
<SO>Best Evid Health Care Cochrane Colloq 7th 1999 Univ S Tommaso Daquino</SO>
<YR>1999</YR>
<VL>7</VL>
<PG>12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rose-1966" MODIFIED="2009-07-29 16:11:00 -0500" MODIFIED_BY="[Empty name]" NAME="Rose 1966" TYPE="JOURNAL_ARTICLE">
<AU>Rose GA</AU>
<TI>Immobilization osteoporosis. A study of the extent, severity, and treatment with bendrofluazide</TI>
<SO>The British journal of surgery</SO>
<YR>1966</YR>
<VL>53</VL>
<NO>9</NO>
<PG>769-74</PG>
<IDENTIFIERS MODIFIED="2009-07-29 16:10:58 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="5911762"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-SHEP-1991" NAME="SHEP 1991" TYPE="JOURNAL_ARTICLE">
<AU>SHEP Cooperative Research Group</AU>
<TI>Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP)</TI>
<SO>JAMA</SO>
<YR>1991</YR>
<VL>265</VL>
<PG>3255-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobel-1983" MODIFIED="2010-11-17 16:35:54 -0600" MODIFIED_BY="[Empty name]" NAME="Sobel 1983" TYPE="JOURNAL_ARTICLE">
<AU>Sobel KG, McCart GM</AU>
<TI>Drug use and accidental falls in an intermediate care facility</TI>
<SO>Drug Intell Clin Pharm</SO>
<YR>1983</YR>
<VL>17</VL>
<NO>7-8</NO>
<PG>539-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Transbol-1982" NAME="Transbol 1982" TYPE="JOURNAL_ARTICLE">
<AU>Transbol I, Christensen MS, Jensen GF, Christiansen C, McNair P</AU>
<TI>Thiazide for the postponement of postmenopausal bone loss</TI>
<SO>Metabolism</SO>
<YR>1982</YR>
<VL>31</VL>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wasnich-1995" NAME="Wasnich 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wasnich RD, Davis JW, He YF, Petrovich H, Ross PD</AU>
<TI>A randomized, double-masked, placebo-controlled trial of chlorthalidone and bone loss in elderly women</TI>
<SO>Osteoporos Int</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>247-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wells" MODIFIED="2010-11-23 23:29:07 -0600" MODIFIED_BY="[Empty name]" NAME="Wells" TYPE="OTHER">
<AU>Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P</AU>
<TI>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses</TI>
<SO>URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm</SO>
<YR>2004</YR>
<VL>(Accessed on July 5, 2004)</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woolcott-2009" MODIFIED="2011-07-24 00:45:24 -0500" MODIFIED_BY="[Empty name]" NAME="Woolcott 2009" TYPE="JOURNAL_ARTICLE">
<AU>Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, Marra CA</AU>
<TI>Meta-analysis of the impact of 9 medication classes on falls in elderly persons</TI>
<SO>Arch Intern Med</SO>
<YR>2009</YR>
<VL>169</VL>
<NO>21</NO>
<PG>1952-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wright-2009" MODIFIED="2011-08-31 15:51:40 -0500" MODIFIED_BY="James M Wright" NAME="Wright 2009" TYPE="COCHRANE_REVIEW">
<AU>Wright JM, Musini V</AU>
<TI>First-line drugs for hypertension</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-08-31 15:51:40 -0500" MODIFIED_BY="James M Wright">
<IDENTIFIER MODIFIED="2011-08-31 15:51:40 -0500" MODIFIED_BY="James M Wright" TYPE="DOI" VALUE="10.1002/14651858.CD001841.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zerwekh-1980" MODIFIED="2010-11-21 14:12:38 -0600" MODIFIED_BY="[Empty name]" NAME="Zerwekh 1980" TYPE="JOURNAL_ARTICLE">
<AU>Zerwekh JE, Pak CY</AU>
<TI>Selective effects of thiazide therapy on serum 1 alpha,25-dihydroxyvitamin D and intestinal calcium absorption in renal and absorptive hypercalciurias</TI>
<SO>Metabolism</SO>
<YR>1980</YR>
<VL>29</VL>
<NO>1</NO>
<PG>13-7</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2010-11-21 22:49:16 -0600" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-11-22 00:03:16 -0600" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-11-22 00:02:51 -0600" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-20 17:33:25 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barengolts-2001">
<CHAR_METHODS MODIFIED="2009-12-13 12:50:06 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-13 12:50:50 -0600" MODIFIED_BY="[Empty name]">
<P>218 patients admitted to Chicago VA Hospital for hip fracture and 218 race- and age-matched controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:33:25 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:32:46 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:33:19 -0600" MODIFIED_BY="[Empty name]">
<P>Unclear how thiazide use was ascertained. Hip fracture was ascertained by VA hospital records</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 11:20:53 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cauley-1993">
<CHAR_METHODS MODIFIED="2010-11-20 11:17:48 -0600" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 11:20:53 -0600" MODIFIED_BY="[Empty name]">
<P>9704 ambulatory non-black women aged 65 and above from 4 clinical centers in the United States (Baltimore, MD, Minneapolis, MN, Portland, OR, and Monogahela Valley, PA)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 11:18:29 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 11:17:06 -0600" MODIFIED_BY="[Empty name]">
<P>Incident fracture, adjusted for age</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 11:17:25 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by a questionnaire, interview and examination. Incident fractures were ascertained every 4 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:52:54 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cumming-1993">
<CHAR_METHODS MODIFIED="2009-06-03 15:27:22 -0500" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 17:36:13 -0600" MODIFIED_BY="[Empty name]">
<P>209 cases from hospitals, 207 controls from private homes and nursing homes</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:35:10 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:36:55 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:52:54 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from the participants or their proxys by a questionnaire. Hip fracture cases were ascertained from hip fracture team in the hospital and from emergency department log books in Westmead Hospital, review of ED log book in 4 hospitals, contact with admissions office in 4 hospitals, contact with medical record department in 2 hospitals, and from a rehabilitation specialist in one hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 11:20:25 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cummings-1995">
<CHAR_METHODS MODIFIED="2009-12-13 13:03:20 -0600" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 11:20:25 -0600" MODIFIED_BY="[Empty name]">
<P>9516 white women age 65 and above who are able to walk from 4 geographic regions in the United States (Portland, OR, Minneapolis, MN, Baltimore, MD and Monongahela Valley, PA)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 11:19:38 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 11:19:22 -0600" MODIFIED_BY="[Empty name]">
<P>Incident fracture adjusted for age. </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 11:19:32 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by structured interviews. Hip fracture was ascertained by postcard or telephone contact every 4 months, confirmed by reviewing radiographs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 18:01:11 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Felson-1991">
<CHAR_METHODS MODIFIED="2010-11-20 18:01:11 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 17:38:19 -0600" MODIFIED_BY="[Empty name]">
<P>176 postmenopausal female members of Framingham Cohort and 672 age-matched controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:37:50 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:37:45 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:37:41 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by patients' reports during biennial examinations. Hip frature was ascertained by patients' reports during biennial examinations &amp; telephone calls, hospital records, death reviews, fracture list of Framingham Study.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 11:24:15 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feskanich-1997">
<CHAR_METHODS MODIFIED="2010-11-20 11:22:58 -0600" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 11:22:53 -0600" MODIFIED_BY="[Empty name]">
<P>83, 728 women nurses, age 35-61, from the United States who participated in the Nurses Health Study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 11:23:55 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 11:24:15 -0600" MODIFIED_BY="[Empty name]">
<P>Incident hip fracture adjusted for age and follow-up period</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 11:23:47 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by initial and biennial follow-up mailed questionnaire asking current use and duration. Hip fracture was ascertained by initial and biennial follow-up mailed questionnaire to the participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:53:14 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grisso-1994">
<CHAR_METHODS MODIFIED="2010-11-20 18:01:19 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-21 23:53:14 -0600" MODIFIED_BY="[Empty name]">
<P>144 black women admitted to New York City and Philadelphia hospitals and 388 controls</P>
<P>218 controls lived in the community, and matched for age, ZIP code and telephone exchange. 181 controls were hospitalised women matched for age and hospital.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:41:26 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:44:19 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:41:17 -0600" MODIFIED_BY="[Empty name]">
<P>Hip fracture was ascertained by x-rays and obtained from admission records. Thiazide use was ascertained by interviewing participants.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:53:09 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-1998">
<CHAR_METHODS MODIFIED="2010-11-21 23:53:05 -0600" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 11:25:34 -0600" MODIFIED_BY="[Empty name]">
<P>1608 residents, age 75 and above who has not had a hip fracture, from Kungsholmen District of Stockholm, Sweden.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 11:26:06 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-21 23:53:07 -0600" MODIFIED_BY="[Empty name]">
<P>Incident hip fracture adjusted for age, gender, education, institutional residence status, activities of daily living, visual problem, history of stroke, history of tumour and cognitive impairment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:53:09 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained during interviews. Use is defined as any use within 2 weeks before the date of interview. Hip fracture cases were defined through computerized in-patient register system that covers all hospitals in Stockholm area.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:53:22 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heidrich-1991">
<CHAR_METHODS MODIFIED="2009-07-23 10:13:51 -0500" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-21 23:53:19 -0600" MODIFIED_BY="[Empty name]">
<P>462 patients aged 50 &amp; above, hospitalised for hip fractures in Western Washington State, USA. Equal number of Age and sex-matched population-based controls.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:39:15 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:45:02 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:53:22 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from medical records and computerized pharmacy records. Hip fracture was ascertained from hospital discharge records showing primary ICD-9 code of 820 or equivalent.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:53:26 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herings-1996">
<CHAR_METHODS MODIFIED="2009-06-03 13:47:59 -0500" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-21 23:53:26 -0600" MODIFIED_BY="[Empty name]">
<P>386 patients hospitalised for femur fractures aged 45 and above who were residents of a defined population from The Netherlands. An age-, sex-, pharmacy-, and general practitioner-matched control was randomly selected from drug-dispensing records for each case.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:46:01 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:45:44 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:45:55 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from computerized pharmacy records. Femur fracture was ascertained from hospital records showing admission with ICD-9 code of 820 (fracture of neck of femur) or 821 (fracture of other and unspecified parts of femur).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 18:00:53 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jensen1991">
<CHAR_METHODS MODIFIED="2010-11-20 18:00:53 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 17:48:19 -0600" MODIFIED_BY="[Empty name]">
<P>200 consecutive patients (age&gt;59) admitted with femoral neck fracture in a hospital in Denmark and 200 controls selected from social security register, matched by age, sex, nursing home residency and number of hospital admissions.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:48:24 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:48:37 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:47:47 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by interviewing the participants by one of the 3 physicians within 4 days of hospital admission. Hip fracture was ascertained by hospital admission diagnosis.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 11:29:15 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LaCroix-1990">
<CHAR_METHODS MODIFIED="2010-11-20 11:27:43 -0600" MODIFIED_BY="[Empty name]">
<P>Cohort study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 11:28:40 -0600" MODIFIED_BY="[Empty name]">
<P>9518 participants from 3 geographic regions of the United States (East Boston, MA, New Haven, CT, Iowa and Washington Couties, IA)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 11:29:02 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 11:29:04 -0600" MODIFIED_BY="[Empty name]">
<P>Incident hip fracture adjusted for age, gender, impaired mobility, body mass index and smoking status</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 11:29:15 -0600" MODIFIED_BY="[Empty name]">
<P>Thizide use was ascertained by interviews during household surveys. Hip fracture was ascertained by annual follow-up interviews.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 17:51:12 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paganini_x002d_Hill-1981">
<CHAR_METHODS MODIFIED="2009-07-23 13:41:42 -0500" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 17:51:12 -0600" MODIFIED_BY="[Empty name]">
<P>83 females with hip fracture fro greater Los Angeles area, California, U.S.A., and166 controls matched by age, race and date of entry to the community.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:49:24 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:49:21 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:49:19 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by personal interviews and abstracts of medical records. Hip fracture was ascertained from hospital discharge records.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:53:37 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rashiq-1986">
<CHAR_METHODS MODIFIED="2010-11-20 18:01:34 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 17:52:45 -0600" MODIFIED_BY="[Empty name]">
<P>102 patients (age 60 and above) with hip fracture from University Hospital, Nottingham, UK and 204 age- and sex-matched controls</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:53:03 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:53:26 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:53:37 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by review of medical records during a year before the date of fracture. Hip fracture was ascertained by operating theatre records from the hospital.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 18:01:41 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-1989">
<CHAR_METHODS MODIFIED="2010-11-20 18:01:41 -0600" MODIFIED_BY="[Empty name]">
<P>Case control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 17:54:51 -0600" MODIFIED_BY="[Empty name]">
<P>905 patients (age 65 and above) with hip fracture and 5131 age- and sex-matched controls selected from residents of Saskatchewan, Canada</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:56:15 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 17:56:26 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:56:12 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from computerized pharmacy records. Hip fracture was ascertained from ICD-9 codes with primary or secondary diagnoses of hip fractures from hospital discharged records.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-20 18:06:16 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rejnmark-2005">
<CHAR_METHODS MODIFIED="2009-07-29 09:40:07 -0500" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 18:00:02 -0600" MODIFIED_BY="[Empty name]">
<P>64,999 patients aged 40 and above with fractures selected from hospital discharge records of national health system in Denmark and 194,111 age and gender-matched controls selected from national civil registration system. Number of patients with hip fracture was10319 (out of 64,999 cases)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 17:57:15 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 18:06:16 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 17:57:08 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by national electronic pharmacy database. Hip fracture was ascertained by hospital discharge records from nationwide electronic medical records</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:53:44 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schoofs-2003">
<CHAR_METHODS MODIFIED="2010-11-20 18:02:00 -0600" MODIFIED_BY="[Empty name]">
<P>Prospective cohort study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 18:03:38 -0600" MODIFIED_BY="[Empty name]">
<P>7891 residents of Ommord (Rotterdam, Netherlands) aged 55 and above who did not have hip fracture before 6/1/91 </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 18:02:37 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-21 23:53:44 -0600" MODIFIED_BY="[Empty name]">
<P>Incident hip fracture adjusted for age, gender, lower limb disability, oestrogen use, and smoking status</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 18:03:54 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from the computer database of pharmacies where the participants filled their prescriptions. Hip fractures were reported by the doctors of the participants through computerized system (80%). Research physicians annually checked medical records of the participants not covered by computer system (20%).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-21 23:54:31 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stevens-1989">
<CHAR_METHODS MODIFIED="2010-11-20 18:04:02 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-21 23:54:31 -0600" MODIFIED_BY="[Empty name]">
<P>173 patients with new non-pathological hip fractures from hospital admissions and 134 age and sex-matched controls from non-emergency surgery admissions in Southeast Thames Region</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 18:05:59 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 18:06:24 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:54:11 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from interviews with patients and review of their medical records, validated independently by questionnaires to general practitioners. Hip fracture was ascertained from casualty and orthopedic ward record review of hospitals in Southeast Thames Region.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-22 00:02:24 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taggart-1988">
<CHAR_METHODS MODIFIED="2010-11-21 23:56:53 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-22 00:02:24 -0600" MODIFIED_BY="[Empty name]">
<P>280 women admitted to a city hospital with hip fracture and 145 controls from general academic family practice list in North Ireland</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-21 23:55:47 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-21 23:56:29 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:55:29 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by taking careful medication histories from patients and family doctors. Hip fracture was ascertained by admission diagnoses.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-22 00:02:48 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2001">
<CHAR_METHODS MODIFIED="2010-11-22 00:02:48 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-22 00:01:04 -0600" MODIFIED_BY="[Empty name]">
<P>1222 individuals, age 65 and above, hospitalised for surgical repair of hip fracture and 4888 age- and gender-matched controls from New Jersy Medicaid Program in the United States</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-21 23:58:24 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-21 23:58:49 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-21 23:58:40 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained by pharmacy claim data. Hip fracture was ascertained by the claim for surgical repair of hip fracture.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-22 00:02:51 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weiland-1997">
<CHAR_METHODS MODIFIED="2010-11-22 00:02:51 -0600" MODIFIED_BY="[Empty name]">
<P>Case-control study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-20 18:08:06 -0600" MODIFIED_BY="[Empty name]">
<P>311 females age 70-79 yrs with hip fracture and 414 controls from West Germany</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-20 18:07:14 -0600" MODIFIED_BY="[Empty name]">
<P>N/A</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-20 18:07:08 -0600" MODIFIED_BY="[Empty name]">
<P>Association of thiazide use and hip fracture</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-20 18:07:07 -0600" MODIFIED_BY="[Empty name]">
<P>Thiazide use was ascertained from patients' records. Hip fracture was ascertained by the reports from the patients' doctors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-11-22 00:03:16 -0600" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-07-24 15:33:38 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adland_x002d_Davenport-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 15:33:38 -0500" MODIFIED_BY="[Empty name]">
<P>Fracture data is available only for hip, wrist, vertebra and wrist combined.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 09:42:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Allen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 09:42:33 -0500" MODIFIED_BY="[Empty name]">
<P>Referenced to another article on Annals of Internal Medicine (Sept 16, 2003). Not an original study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 15:31:04 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 15:31:04 -0500" MODIFIED_BY="[Empty name]">
<P>Pt education article. Not original research.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-07 17:06:11 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anonymous-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-07 17:06:11 -0500" MODIFIED_BY="[Empty name]">
<P>Not an original investigation. Made reference to Schoofs 2003.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 10:06:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benetos-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 10:06:27 -0500" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 11:16:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bolland-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 11:16:15 -0500" MODIFIED_BY="[Empty name]">
<P>Bone density was the only outcome addressed. No data on rate of fracture.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-19 11:56:16 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bouwmeester-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-19 11:56:16 -0500" MODIFIED_BY="[Empty name]">
<P>Not an original investigation. Made reference to Schoofs 2003.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-27 10:15:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cumming-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-27 10:15:17 -0500" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 15:32:54 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grisso-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 15:32:54 -0500" MODIFIED_BY="[Empty name]">
<P>Thiazide use was not addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 15:59:25 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hale-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 15:59:25 -0500" MODIFIED_BY="[Empty name]">
<P>No specific data for thiazide users. Lumped as diuretics, which included non-thiazides.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-07 17:00:15 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jergas-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-07 17:00:15 -0500" MODIFIED_BY="[Empty name]">
<P>Only used bone density as the primary outcome measure. No fracture outcomes were analyzed. </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-19 11:40:28 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-19 11:40:28 -0500" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 09:42:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-LaCroix-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 09:42:57 -0500" MODIFIED_BY="[Empty name]">
<P>Bone density was the only outcome addressed. No data on rate of fracture.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 18:17:03 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lim-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 18:17:03 -0500" MODIFIED_BY="[Empty name]">
<P>Bone mineral density only. No fracture.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 09:43:17 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nguyen-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 09:43:17 -0500" MODIFIED_BY="[Empty name]">
<P>Only OR for total fractures can be extracted from the article. OR for hip fractures in reference to thiazide use cannot be extracted.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 16:19:46 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 16:19:46 -0500" MODIFIED_BY="[Empty name]">
<P>It is an editorial; not an original study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 16:18:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reid-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 16:18:44 -0500" MODIFIED_BY="[Empty name]">
<P>Bone density was used as outcome. Fracture was not used as an outcome measure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-22 00:03:10 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sernbo-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-22 00:03:10 -0600" MODIFIED_BY="[Empty name]">
<P>No data on thiazide use was available. It was analysed only as diuretic use.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-24 17:59:35 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sigurdsson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-24 17:59:35 -0500" MODIFIED_BY="[Empty name]">
<P>Bone density was used as outcome. Fracture was not used as an outcome measure.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-07 17:04:16 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thapa-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-07 17:04:16 -0500" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 09:43:36 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wasnich-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 09:43:36 -0500" MODIFIED_BY="[Empty name]">
<P>Only fracture of lumbar spine was addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-22 00:03:16 -0600" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wasnich-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-22 00:03:16 -0600" MODIFIED_BY="[Empty name]">
<P>Hip fracture outcome was not addressed. Fractures were classified as spine fracture and non-spine fractures</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-29 09:44:14 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wasnich-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-29 09:44:14 -0500" MODIFIED_BY="[Empty name]">
<P>Rate of bone loss in calcaneus and radius were used as outcome measures. Hip fracture outcome was not addressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-19 11:42:27 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiens-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-19 11:42:27 -0500" MODIFIED_BY="[Empty name]">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-11-21 19:05:05 -0600" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-11-20 11:18:14 -0600" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-20 11:18:14 -0600" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2011-07-30 15:47:52 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2011-07-30 15:44:41 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-07-30 15:44:25 -0500" MODIFIED_BY="[Empty name]">Summary of findings (cohort studies)</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TD COLSPAN="4">
<P>
<B>Thiazide users compared with nonusers for the risk of hip fracture</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>adults 40 years or older</P>
<P>
<B>Intervention: </B>use of thiazide diuretics</P>
<P>
<B>Comparison: </B>nonusers</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Hip Fracture</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>
<B>RR 0.76</B> (0.64 to 0.89)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2011-07-30 15:47:52 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-07-30 15:45:35 -0500" MODIFIED_BY="[Empty name]">Summary of findings (case-control studies)</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TD COLSPAN="4">
<P>
<B>Thiazide users compared with nonusers for the risk of hip fracture</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Patient or population: </B>adults 40 years or older</P>
<P>
<B>Intervention: </B>use of thiazide diuretics</P>
<P>
<B>Comparison: </B>nonusers</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Hip Fracture</B>
</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>summary statistic not calculated</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Summary statistic not calculated due to high heterogeneity</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-07-31 13:45:19 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-07-23 22:48:34 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-17 16:49:48 -0600" MODIFIED_BY="[Empty name]">Risk of Bias Assessment for Cohort Studies</TITLE>
<TABLE COLS="4" ROWS="7">
<TR>
<TD>
<P>
<B>Study </B>
</P>
</TD>
<TD>
<P>
<B>Selection </B>
</P>
</TD>
<TD>
<P>
<B>Comparability </B>
</P>
</TD>
<TD>
<P>
<B>Outcome </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Cauley 1993</P>
</TD>
<TD>
<P>***</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>***</P>
</TD>
</TR>
<TR>
<TD>
<P>Cummings 1995</P>
</TD>
<TD>
<P>****</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>***</P>
</TD>
</TR>
<TR>
<TD>
<P>Faskanich 1997</P>
</TD>
<TD>
<P>*</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>*</P>
</TD>
</TR>
<TR>
<TD>
<P>Guo 1997</P>
</TD>
<TD>
<P>****</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>***</P>
</TD>
</TR>
<TR>
<TD>
<P>LaCroix 1990</P>
</TD>
<TD>
<P>****</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Schoofs 2003</P>
</TD>
<TD>
<P>****</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>***</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-11-17 16:54:40 -0600" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-17 16:54:06 -0600" MODIFIED_BY="[Empty name]">Risk of Bias Assessment for Case-control Studies</TITLE>
<TABLE COLS="4" ROWS="16">
<TR>
<TD>
<P>
<B>Study </B>
</P>
</TD>
<TD>
<P>
<B>Selection </B>
</P>
</TD>
<TD>
<P>
<B>Comparability </B>
</P>
</TD>
<TD>
<P>
<B>Exposure </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Barengolts 2001</P>
</TD>
<TD>
<P>*</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Cumming 1993</P>
</TD>
<TD>
<P>***</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>***</P>
</TD>
</TR>
<TR>
<TD>
<P>Felson 1991</P>
</TD>
<TD>
<P>***</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>***</P>
</TD>
</TR>
<TR>
<TD>
<P>Grisso 1994</P>
</TD>
<TD>
<P>* *</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>*</P>
</TD>
</TR>
<TR>
<TD>
<P>Heidrich 1991</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Herings 1996</P>
</TD>
<TD>
<P>***</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1991</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>*</P>
</TD>
</TR>
<TR>
<TD>
<P>Paganini-Hills 1981</P>
</TD>
<TD>
<P>***</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Rashiq 1986</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Ray 1989</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Renjmark 2005</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Stevens 1989</P>
</TD>
<TD>
<P>*</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>****</P>
</TD>
</TR>
<TR>
<TD>
<P>Taggart 1988</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>*</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 2001</P>
</TD>
<TD>
<P>****</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
<TR>
<TD>
<P>Weiland 1997</P>
</TD>
<TD>
<P>***</P>
</TD>
<TD>
<P>**</P>
</TD>
<TD>
<P>**</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-11-23 23:06:39 -0600" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-11-17 16:57:06 -0600" MODIFIED_BY="[Empty name]">Cohort Studies</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD VALIGN="MIDDLE">
<P>
<B>Study </B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>Female (%) </B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>Ethnicity </B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>Age </B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B> N </B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>Location </B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>Mean follow-up yrs  (person-yrs) </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Cauley 1993</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>Non-black</P>
</TD>
<TD>
<P>&gt;65</P>
</TD>
<TD>
<P>9,704</P>
</TD>
<TD>
<P>U.S. (MD, MN, OR, PA)</P>
</TD>
<TD>
<P>3.3 (32,217)</P>
</TD>
</TR>
<TR>
<TD>
<P>Cummings 1995</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>White</P>
</TD>
<TD>
<P>&gt;65</P>
</TD>
<TD>
<P>9,516</P>
</TD>
<TD>
<P>U.S. (MD, MN, OR, PA )</P>
</TD>
<TD>
<P>4.1  (39,015)</P>
</TD>
</TR>
<TR>
<TD>
<P>Faskanich 1997</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>98% White</P>
</TD>
<TD>
<P>&gt;35</P>
</TD>
<TD>
<P>83,728</P>
</TD>
<TD>
<P>U.S.</P>
</TD>
<TD>
<P>9.2 (771,605)</P>
</TD>
</TR>
<TR>
<TD>
<P>Guo 1997</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;75</P>
</TD>
<TD>
<P>1,608</P>
</TD>
<TD>
<P>Sweden</P>
</TD>
<TD>
<P>4.4 (7,124)</P>
</TD>
</TR>
<TR>
<TD>
<P>LaCroix 1990</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;65</P>
</TD>
<TD>
<P>9,518</P>
</TD>
<TD>
<P>U.S. (MA, CT, IA)</P>
</TD>
<TD>
<P>3.6 (34,426)</P>
</TD>
</TR>
<TR>
<TD>
<P>Schoofs 2003</P>
</TD>
<TD>
<P>61</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;55</P>
</TD>
<TD>
<P>7,891</P>
</TD>
<TD>
<P>Netherlands</P>
</TD>
<TD>
<P>7.4 (58,009)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2011-07-24 16:06:43 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-11-17 17:01:48 -0600" MODIFIED_BY="[Empty name]">Case-control Studies</TITLE>
<TABLE COLS="6" ROWS="16">
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>
<B>Female (%)</B>
</P>
</TD>
<TD>
<P>
<B>Ethnicity</B>
</P>
</TD>
<TD>
<P>
<B>Age</B>
</P>
</TD>
<TD>
<P>
<B>N</B>
</P>
<P>
<B>(Cases; Control)</B>
</P>
</TD>
<TD>
<P>
<B>Location</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Barengolts 2001</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>40% black</P>
</TD>
<TD>
<P>&gt;55</P>
</TD>
<TD>
<P>218; 218</P>
</TD>
<TD>
<P>U.S (Chicago, IL)</P>
</TD>
</TR>
<TR>
<TD>
<P>Cumming 1993</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;65</P>
</TD>
<TD>
<P>299; 207</P>
</TD>
<TD>
<P>Sydney, Australia</P>
</TD>
</TR>
<TR>
<TD>
<P>Felson 1991</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>postmenopausal</P>
</TD>
<TD>
<P>176; 672</P>
</TD>
<TD>
<P>U.S. (Framingham, MA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Grisso 1994</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>100% black</P>
</TD>
<TD>
<P>&gt;45</P>
</TD>
<TD>
<P>144; 399</P>
</TD>
<TD>
<P>U.S. (NYC &amp; Philadelphia)</P>
</TD>
</TR>
<TR>
<TD>
<P>Heidrich 1991</P>
</TD>
<TD>
<P>76</P>
</TD>
<TD>
<P>97% white</P>
</TD>
<TD>
<P>&gt;50</P>
</TD>
<TD>
<P>462; 462</P>
</TD>
<TD>
<P>U.S. (MA, CT, IA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Herings 1996</P>
</TD>
<TD>
<P>75</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;45</P>
</TD>
<TD>
<P>386; 386</P>
</TD>
<TD>
<P>Netherlands</P>
</TD>
</TR>
<TR>
<TD>
<P>Jensen 1991</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;59</P>
</TD>
<TD>
<P>200; 200</P>
</TD>
<TD>
<P>Denmark</P>
</TD>
</TR>
<TR>
<TD>
<P>Paganini-Hill 1981</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>Postmenopausal &lt;80</P>
</TD>
<TD>
<P>83; 166</P>
</TD>
<TD>
<P>U.S. (Los Angeles, CA)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rashiq 1986</P>
</TD>
<TD>
<P>88</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;60</P>
</TD>
<TD>
<P>102; 204</P>
</TD>
<TD>
<P>UK</P>
</TD>
</TR>
<TR>
<TD>
<P>Ray 1989</P>
</TD>
<TD>
<P>74</P>
</TD>
<TD>
<P>95% white</P>
</TD>
<TD>
<P>&gt;65</P>
</TD>
<TD>
<P>905; 5,131</P>
</TD>
<TD>
<P>Canada</P>
</TD>
</TR>
<TR>
<TD>
<P>Renjmark 2005</P>
</TD>
<TD>
<P>66</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;40</P>
</TD>
<TD>
<P>64,699; 194,111</P>
</TD>
<TD>
<P>Denmark</P>
</TD>
</TR>
<TR>
<TD>
<P>Stevens 1989</P>
</TD>
<TD>
<P>79</P>
</TD>
<TD>
<P>Mostly white</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>173; 134</P>
</TD>
<TD>
<P>UK</P>
</TD>
</TR>
<TR>
<TD>
<P>Taggart 1988</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>&gt;74</P>
</TD>
<TD>
<P>280; 145</P>
</TD>
<TD>
<P>North Ireland</P>
</TD>
</TR>
<TR>
<TD>
<P>Wang 2001</P>
</TD>
<TD>
<P>84</P>
</TD>
<TD>
<P>86% white</P>
</TD>
<TD>
<P>&gt;65</P>
</TD>
<TD>
<P>1,222; 4,888</P>
</TD>
<TD>
<P>U.S. (NJ)</P>
</TD>
</TR>
<TR>
<TD>
<P>Weiland 1997</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>unknown</P>
</TD>
<TD>
<P>70-79</P>
</TD>
<TD>
<P>311; 414</P>
</TD>
<TD>
<P>West Germany</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2011-07-31 13:45:19 -0500" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2011-07-24 16:37:17 -0500" MODIFIED_BY="[Empty name]">Covariates adjusted in cohort studies</TITLE>
<TABLE COLS="2" ROWS="7">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Adjustment</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cauley 1993</P>
</TD>
<TD VALIGN="TOP">
<P>age, weight, functional status, total calcium intake, years of estrogen replacement, self-reported health status</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cummings 1995</P>
</TD>
<TD VALIGN="TOP">
<P>age</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Feskanich 1997</P>
</TD>
<TD VALIGN="TOP">
<P>age, follow-up period, BMI, menopausal status, postmenopausal estrogen use, cigarette smoking, dietary intake of calcium, vitamin D, protein, alcohol, caffeine and sodium, calcium supplements, previous diagnosis of heart disease, previous diagnosis of osteoporosis.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Guo 1998</P>
</TD>
<TD VALIGN="TOP">
<P>age, gender, education, residence, limitation of activities of daily living, visual problem, history of stroke, history of tumor, cognitive impairment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Lacroix 1990</P>
</TD>
<TD VALIGN="TOP">
<P>age, gender, impaired mobility, BMI, current smoking, former smoking</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Schoofs 2003</P>
</TD>
<TD VALIGN="TOP">
<P>age, gender, lower limb disability, BMI, oestrogen use, current smoking</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2011-07-24 16:37:44 -0500" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2011-07-24 15:54:12 -0500" MODIFIED_BY="[Empty name]">Covariates adjusted in case-control studies</TITLE>
<TABLE COLS="2" ROWS="16">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Covariates adjusted</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Barengolts 2001</P>
</TD>
<TD VALIGN="TOP">
<P>age, body weight, BMI, statin use</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cumming 1993</P>
</TD>
<TD VALIGN="TOP">
<P>age, sex, type of residence, alcohol consumption, BMI, cognitive status, dairy consumption, health status, physical activity, proxy status, smoking history, use of other medications</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Felson 1991</P>
</TD>
<TD VALIGN="BOTTOM">
<P>BMI, oestrogen use, number of cigarettes smoked, alcohol consumption, age at menopause</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Grisso 1994</P>
</TD>
<TD VALIGN="BOTTOM">
<P>age group, zip code, telephone exchange, age as continuous variable, BMI, BMI-squared</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Heidrich 1991</P>
</TD>
<TD VALIGN="BOTTOM">
<P>alcoholism, organic brain syndrome, leg paralysis, history of stroke, days of hospitalizations in preceding year, nursing home residence, BMI, use of phenobarbital, corticosteroids and furosemide</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Herings 1996</P>
</TD>
<TD VALIGN="BOTTOM">
<P>days hospitalised before index date, history of hospitalizations for nonhip fractures, presence of severe rheumatological disease, anaemia, organic brain syndrome, cerebrovascular disease, peripheral arterial disease, incontinence, osteoporosis, current use of benzodiazepines, antidepressants, H-1 antagonists, neuroleptics, furosemide and corticosteroids</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Jensen 1991</P>
</TD>
<TD VALIGN="BOTTOM">
<P>?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Paganini-Hills 1981</P>
</TD>
<TD VALIGN="BOTTOM">
<P>?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Rashiq 1986</P>
</TD>
<TD VALIGN="BOTTOM">
<P>?</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Ray 1989</P>
</TD>
<TD VALIGN="BOTTOM">
<P>demographics, hospital admissions, use of other medications</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Renjmark 2005</P>
</TD>
<TD VALIGN="BOTTOM">
<P>prior fracture, Charlon index,  hx of using corticosteroid, antiepileptics, other diuretics, other antihypertensives, anxiolytics/sedatives, neuroleptics, and antidepressants, number of days hospitalised in prior year, number of contacts with the doctors in prior year, employment status, income, living alone</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Stevens 1989</P>
</TD>
<TD VALIGN="BOTTOM">
<P>age, gender</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Taggart 1988</P>
</TD>
<TD VALIGN="BOTTOM">
<P>age</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Wang 2001</P>
</TD>
<TD VALIGN="BOTTOM">
<P>age, gender, race, use of zolpidem, benzodiazepines, antipsychotics, antidepressants, other psychoactive medication, comorbidity index, hospital days in prior 6 months, nursing home days in prior 6 months</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Weiland 1997</P>
</TD>
<TD VALIGN="BOTTOM">
<P>age, BMI, smoking habits, alcohol consumption, uncontrolled hypertension, impaired mobility, cardiac insufficiency, cerebral insufficiency</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>BMI = body mass index</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-09-04 18:42:53 -0500" MODIFIED_BY="James M Wright">
<COMPARISON ID="CMP-001" MODIFIED="2011-09-04 18:42:53 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Current thiazide users vs nonusers (cohort studies)</NAME>
<IV_OUTCOME CHI2="2.930940773386295" CI_END="0.8921069960891124" CI_START="0.6429173768912824" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="0.7573315587191475" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.04958305478936499" LOG_CI_START="-0.19184483588727386" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.12071394533831947" MODIFIED="2011-09-04 18:42:53 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5694480744834094" P_Q="1.0" P_Z="8.804132187848005E-4" Q="0.0" RANDOM="NO" SCALE="4.83" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="99.99999999999997" Z="3.326191805963838">
<NAME>Hip Fracture</NAME>
<GROUP_LABEL_1>Thiazide</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours thiazide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Risk Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.1199946420102351" CI_START="0.6003611420766582" EFFECT_SIZE="0.8200007697539087" ESTIMABLE="YES" ESTIMATE="-0.19845" LOG_CI_END="0.0492159450354004" LOG_CI_START="-0.221587424902801" LOG_EFFECT_SIZE="-0.08618573993370032" MODIFIED="2010-11-20 11:56:51 -0600" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.15907124" STUDY_ID="STD-Cauley-1993" TOTAL_1="0" TOTAL_2="0" WEIGHT="27.59741182302905"/>
<IV_DATA CI_END="0.9899970764042058" CI_START="0.4809140519510654" EFFECT_SIZE="0.6900025401643497" ESTIMABLE="YES" ESTIMATE="-0.37106" LOG_CI_END="-0.004366087931132463" LOG_CI_START="-0.3179325329789088" LOG_EFFECT_SIZE="-0.16114931045502065" MODIFIED="2009-12-13 22:49:33 -0600" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.184190482" STUDY_ID="STD-Feskanich-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.583409709109148"/>
<IV_DATA CI_END="1.8699814323289583" CI_START="0.6470650157026557" EFFECT_SIZE="1.0999998022152604" ESTIMABLE="YES" ESTIMATE="0.09531" LOG_CI_END="0.27183729430275066" LOG_CI_START="-0.1890520801623528" LOG_EFFECT_SIZE="0.041392607070198914" MODIFIED="2009-12-13 22:49:33 -0600" MODIFIED_BY="[Empty name]" ORDER="27" SE="0.2707287" STUDY_ID="STD-Guo-1998" TOTAL_1="0" TOTAL_2="0" WEIGHT="9.527590698037814"/>
<IV_DATA CI_END="0.9399967387081583" CI_START="0.49191904101294714" EFFECT_SIZE="0.680001686954242" ESTIMABLE="YES" ESTIMATE="-0.38566" LOG_CI_END="-0.026873653169990443" LOG_CI_START="-0.30810636661162577" LOG_EFFECT_SIZE="-0.16749000989080814" MODIFIED="2009-12-13 22:49:33 -0600" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.165197488" STUDY_ID="STD-LaCroix-1990" TOTAL_1="0" TOTAL_2="0" WEIGHT="25.58849887542413"/>
<IV_DATA CI_END="1.0599925209964443" CI_START="0.4755696870449209" EFFECT_SIZE="0.7100002193522448" ESTIMABLE="YES" ESTIMATE="-0.34249" LOG_CI_END="0.025302801018135177" LOG_CI_START="-0.3227858352322246" LOG_EFFECT_SIZE="-0.14874151710704475" MODIFIED="2009-12-13 22:49:33 -0600" MODIFIED_BY="[Empty name]" ORDER="29" SE="0.204468988" STUDY_ID="STD-Schoofs-2003" TOTAL_1="0" TOTAL_2="0" WEIGHT="16.703088894399844"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-08-31 16:42:40 -0500" MODIFIED_BY="James M Wright" NO="2">
<NAME>Current thiazide users vs nonusers (case-control studies)</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-08-31 16:42:40 -0500" MODIFIED_BY="James M Wright" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.81" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hip Fracture</NAME>
<GROUP_LABEL_1>Thiazide users</GROUP_LABEL_1>
<GROUP_LABEL_2>Nonusers</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours thiazide users</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours non-users</GRAPH_LABEL_2>
<EFFECT_MEASURE>Odds Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="0.9799806056060981" CI_START="0.11796143826511805" EFFECT_SIZE="0.3399998848664757" ESTIMABLE="YES" ESTIMATE="-1.07881" LOG_CI_END="-0.008782519166278365" LOG_CI_START="-0.9282599408778157" LOG_EFFECT_SIZE="-0.4685212300220471" MODIFIED="2011-07-24 14:28:36 -0500" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.540105589" STUDY_ID="STD-Barengolts-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.989979485591047" CI_START="0.4826206537221254" EFFECT_SIZE="0.9800026531747605" ESTIMABLE="YES" ESTIMATE="-0.0202" LOG_CI_END="0.29884859935416397" LOG_CI_START="-0.3163940964230553" LOG_EFFECT_SIZE="-0.008772748534445691" MODIFIED="2011-07-24 14:30:27 -0500" MODIFIED_BY="[Empty name]" ORDER="1" SE="0.361396605" STUDY_ID="STD-Cumming-1993" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.3999869516691832" CI_START="0.3400771020512756" EFFECT_SIZE="0.6900025401643497" ESTIMABLE="YES" ESTIMATE="-0.37106" LOG_CI_END="0.14612398793218087" LOG_CI_START="-0.46842260884222214" LOG_EFFECT_SIZE="-0.16114931045502065" MODIFIED="2011-07-24 14:28:38 -0500" MODIFIED_BY="[Empty name]" ORDER="2" SE="0.360987713" STUDY_ID="STD-Felson-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.5999853043429324" CI_START="0.4000065150355634" EFFECT_SIZE="0.8000028410564125" ESTIMABLE="YES" ESTIMATE="-0.22314" LOG_CI_END="0.2041159937358733" LOG_CI_START="-0.39793293511965655" LOG_EFFECT_SIZE="-0.09690847069189164" MODIFIED="2011-07-24 14:28:38 -0500" MODIFIED_BY="[Empty name]" ORDER="19" SE="0.353646521" STUDY_ID="STD-Grisso-1994" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="2.4999804237156913" CI_START="1.0240087778198028" EFFECT_SIZE="1.600000593206933" ESTIMABLE="YES" ESTIMATE="0.470004" LOG_CI_END="0.39793660790982216" LOG_CI_START="0.010303679435089799" LOG_EFFECT_SIZE="0.20412014367245596" MODIFIED="2011-07-24 14:28:39 -0500" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.227697501" STUDY_ID="STD-Heidrich-1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="0.8999877427133863" CI_START="0.27777999456995134" EFFECT_SIZE="0.4999985902819599" ESTIMABLE="YES" ESTIMATE="-0.69315" LOG_CI_END="-0.04576340534755193" LOG_CI_START="-0.5562990349149262" LOG_EFFECT_SIZE="-0.30103122013123906" MODIFIED="2011-07-24 14:30:28 -0500" MODIFIED_BY="[Empty name]" ORDER="4" SE="0.299891156" STUDY_ID="STD-Herings-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="2.0799735331367764" CI_START="0.5300546475434228" EFFECT_SIZE="1.0499998276221105" ESTIMABLE="YES" ESTIMATE="0.04879" LOG_CI_END="0.31805780876767403" LOG_CI_START="-0.27567935322355475" LOG_EFFECT_SIZE="0.021189227772059647" MODIFIED="2011-07-24 14:30:29 -0500" MODIFIED_BY="[Empty name]" ORDER="5" SE="0.348764148" STUDY_ID="STD-Jensen1991" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.9599772086309446" CI_START="0.5308228947463753" EFFECT_SIZE="1.0200003801579676" ESTIMABLE="YES" ESTIMATE="0.019803" LOG_CI_END="0.29225102124251406" LOG_CI_START="-0.27505035399225386" LOG_EFFECT_SIZE="0.008600333625130109" MODIFIED="2011-07-24 14:28:41 -0500" MODIFIED_BY="[Empty name]" ORDER="6" SE="0.333235636" STUDY_ID="STD-Paganini_x002d_Hill-1981" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="0.5799878046367208" CI_START="0.09120807922347306" EFFECT_SIZE="0.22999907311542422" ESTIMABLE="YES" ESTIMATE="-1.46968" LOG_CI_END="-0.236581138220959" LOG_CI_START="-1.0399666901061835" LOG_EFFECT_SIZE="-0.6382739141635712" MODIFIED="2011-07-24 14:30:30 -0500" MODIFIED_BY="[Empty name]" ORDER="7" SE="0.47191265" STUDY_ID="STD-Rashiq-1986" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="0.9199984590748123" CI_START="0.6613072532844196" EFFECT_SIZE="0.7800010602535503" ESTIMABLE="YES" ESTIMATE="-0.24846" LOG_CI_END="-0.03621290006299528" LOG_CI_START="-0.1795967138843686" LOG_EFFECT_SIZE="-0.10790480697368195" MODIFIED="2011-07-24 14:28:42 -0500" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.084224362" STUDY_ID="STD-Ray-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.0799992681108221" CI_START="0.9633347042376323" EFFECT_SIZE="1.0200003801579676" ESTIMABLE="YES" ESTIMATE="0.019803" LOG_CI_END="0.033423461176265434" LOG_CI_START="-0.01622279392600526" LOG_EFFECT_SIZE="0.008600333625130109" MODIFIED="2011-07-24 14:30:31 -0500" MODIFIED_BY="[Empty name]" ORDER="9" SE="0.029162456" STUDY_ID="STD-Rejnmark-2005" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.9699800884011331" CI_START="0.4581294763855234" EFFECT_SIZE="0.9500031296733282" ESTIMABLE="YES" ESTIMATE="-0.05129" LOG_CI_END="0.2944618365467625" LOG_CI_START="-0.33901176450039816" LOG_EFFECT_SIZE="-0.022274963976817764" MODIFIED="2011-07-24 14:30:31 -0500" MODIFIED_BY="[Empty name]" ORDER="10" SE="0.372105529" STUDY_ID="STD-Stevens-1989" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="2.139979819329558" CI_START="0.7301477275768168" EFFECT_SIZE="1.2500005608573637" ESTIMABLE="YES" ESTIMATE="0.223144" LOG_CI_END="0.3304096778374435" LOG_CI_START="-0.13658926209780506" LOG_EFFECT_SIZE="0.09691020786981924" MODIFIED="2011-07-24 14:30:34 -0500" MODIFIED_BY="[Empty name]" ORDER="12" SE="0.274317489" STUDY_ID="STD-Taggart-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.0199954900008652" CI_START="0.7083349487411242" EFFECT_SIZE="0.8499990900735958" ESTIMABLE="YES" ESTIMATE="-0.16252" LOG_CI_END="0.00859825149518439" LOG_CI_START="-0.1497613298930173" LOG_EFFECT_SIZE="-0.07058153919891647" MODIFIED="2011-07-24 14:28:45 -0500" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.093021202" STUDY_ID="STD-Wang-2001" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
<IV_DATA CI_END="1.339991934377805" CI_START="0.6454525406290046" EFFECT_SIZE="0.9300006443366202" ESTIMABLE="YES" ESTIMATE="-0.07257" LOG_CI_END="0.12710218428588638" LOG_CI_START="-0.19013568538932435" LOG_EFFECT_SIZE="-0.03151675055171896" MODIFIED="2011-07-24 14:30:33 -0500" MODIFIED_BY="[Empty name]" ORDER="11" SE="0.186347095" STUDY_ID="STD-Weiland-1997" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0"/>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-09-04 18:42:54 -0500" MODIFIED_BY="James M Wright">
<FIGURE FILENAME="FlowChartofStudySelection_Revised11Dec09.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2009-12-13 22:04:50 -0600" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Figure 1. Flow Chart of Study Selection Process</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-09-04 18:42:54 -0500" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Current thiazide users vs nonusers (Cohort), outcome: Hip Fracture.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApcAAADACAMAAABmprjFAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-08-31 16:42:41 -0500" MODIFIED_BY="James M Wright" NO="3" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Current thiazide users vs nonusers, outcome: Hip Fracture.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApoAAAFACAMAAAArnywZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-09-04 18:42:54 -0500" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: Current thiazide users vs nonusers (cohort studies), outcome: Hip Fracture.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD/gADAwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID///8AAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///9BjlLGAAAUk0lEQVR42u1de2xb1R2+aR5eIIVdk0njj8FII0LTDTX/LH8sSBMl
o2pKylAsVTIdKUNknaiCWopaVSJKo67JGiqySENxURvoTCkJFLllLaBEQjUS9QrO0JptIgNtMBSp
9F4pDTS2VbLYTuJH/LiPc+89j+9TG9/Y93ny+Tvf+Z1zfqdElgCAPFahCAAQCwCxALFRpnVHdeG/
nHxJbEiqrMor9pGXP1/aiL8HHwdi5eWVvPhDTn8jG0ufq6kNGcxCVWgAqqomXxYlCgD0VYVLNWCm
YMVfFv7H/xU6DpIFYuXlxpK1ymJYxg7pn+fbEQCxstUq3WMV2C+pT3IeHwbAY2U1CjVzUM3eAEAs
wy4eZQkUrQrVFVVetsda9ONyck9ZzVCnZbO+uIEqEcRKb+vlahHKWW9lvy0v/ZQlmHcQywAyQghq
mrtfKX4QLHgsPcxK315A4iXHbjL1sqWABjYTS10C10XwatkweGBvVSgLYbyvSmHwgN5wA7OY7pVG
YyACiEUa7jap7RkQwRZiyQu2SpyWnEfyHAYRSKOkGIEQKwBQFQIgFiWIjiWNVhRUALEIQml2SdKM
JJ1vDoELRFFaWWSHuUqeH7+mtEOSIi7p6MM3zoIMUCxigtXrWdzq70XHDohFDJOtTYtb5a2TIANJ
INyw4LFuAQ+gWBYAvIJ5J+uw5s71pf0WuVAKPoBYBLDmf5603/oaPwCxUBWSECx/46LHSr54EMuC
YpFAzeeLfc8RV+Ll2E9uRSwLimUeo7uz3tg3Cj6AWOZxan3WG02nwAdiQBwLcSwoFklcCC5vpngV
rAYjQCxzOJBroMz8avQYglimEJy/P8e7921EjyGIZQr+R9M8VmqzcT8oAWKZQPVUa8732yuugxNE
IGiA9Mt1dalfFgOkCbwy0AdSkADCDQg3oCokZ90NfgaAWIVwYVtGVCFDsJRtY2AFqkJjaG7ryP/h
UOBt0AKKZagijHoKfOqJojJEq9AQXK/2Z5p3V/pvff+86RJ4AcUygMbZgh/PNoIW8FgkgHADFIsA
FEL7APBYmQ+0YjJOxJX1hm/kIpgBxdKHWKAk+60VNWFbALkjoVg6savlnaL79PWs/RDUgGLpQSjs
1bCXN4yZYCCWLkQfda9sFa54x+1FIjaTQLgB4QYoFgBi0QmlWWuEStmBWBaqQs3olAa0VoVPzw+A
HSYgVLhB2X0mV0IZV659L3x9BclnUBVqQ1VrueZ9y1vnwQ4QSxv29OvYuX8P2AGPZQoIN0CxABCL
OkTHdR4w7gM/QKziTcKWKr1e349YFjxWUQyNvqfXY21+swIMgWIVEazRiXwf5fXup+sgWSBWEUzW
XtF9TPnGABgCYhVG00EDBx1sB0PgsQwDcSwLIEhfoVLzSv70RBGXseMAEGvNaIFsDQWI1RcpOQOS
wGPlxYjX4IFdI2gYglh5MS61GvX80ghIgqowH77au67Ap65Ch16+8RlYAsXKgxMNhg+tPAGSINwA
QLHsdFhFZp/OFP5YQSI2ECsnDm00dXh4GxqG5oilquryJkePOBydMnX8hlqsY2iKWKosyyp/vJL8
Xre5E3gxLotQVciVYR+fajV5hvb/QrLIEIurhmDVtR8W2aNoH/S19SCKiXBDXKeWtCr5qnLJNMDx
VuGC6ZKTP9gFmdx8MbgshBsyHdbdxfeZKb7LJrgsECsDz+8icpo2dEUbJ5asqgmbxdPjDZ/0EjlP
wxuYY6gP6aMbKivjvyTeSL3L9uiG2z/SkK4h4iq6y9GSO7EOCqrCFAZIme5ZZMsyHG7IDYxuAKBY
WVAoPptIHisnWPZYMy8cI3ey4J+wDgoUK4Hp8/Xa+Kdpr/oAxmXBYyXQWd+hjVjaJqxiTV8oVrLu
mvAQPZ9nFpIFxVrA9RNParRiGqfY+9ZsAGFALB0eH7kbUBVaAfAKxNKOUKcVzQG4LK0o4/XBLh62
IM3jYRBGdMWaPlKi3WNp3lMZnQZlxDbv0T3ae411mPfBKXRGC61YSovXkvM2TqLHUGzF0gOEG6BY
AIjlJHw/0LO3LsGKYYyyuMRS/KctO3d4awis0QAux2PVlHZYdu6jz944C9qIqVhKr75hDTO69u4/
gFiWoIq1pup3uvbXMEsnvcQeV5GhW0zFevKgpaf3toE2xYE4FuJYUCxtDsv6eIAP4fei4G90w2hY
7xG6BetyOxbIFE6xFH+j5dfwNCOWJRyxwlXtll+jaX0YzBGMWMoTW/Sbd/2S1QuXVQS8xbH6yk7p
PkZfHCuOY2U7sYxhYSDcgHADqsLisC1XqBIDd0Qi1qYJU4erSyi658QmuCyBPFbw/S4DR6Us1s3f
q0zg5vlix7z84DdvgT3CKFa3yZHuV7NeC6AR66CIQ6xqqdW2a7VLlWBPAXDVpfOWVHg5pjwrbRhr
FXZ1NYE+CDdkPIuaj1irvst8BVAVSiSShOrwWPHrwWUJQazgNpsvuA09hkJ4rN6N5lM56lqWY0sv
+COAYgWvGY01pLy7vARNx7VJyGqUF/wESF2vFl3dZOlZCD1T3953sQ4K94qlVMzafs22Cth3hBsk
wnEsQBTzXhxYFghVoV44lB10uBMU4lqxYoH+cieu29odKweJOG4V7q77q/GD9Q9NTjUMe9Z+CBLx
WxWGPu4ycbQZ7+4NYyYYx4q1NaJ1vIw6N3ezEv9P6LH6Pm1EViPhww1S3gEOAKpC8phBEYBYuaAM
Onr5IYTfOQ03dDt7+X90g0ZcKpYS6Hf0+ocDmGPIZaswctfH2nfONcDBRBwrUYSP/RyxLA4VSwn/
0eQZzPZBew/AZa0AB+GG0M907KxK0m1X4/9JPpbiBpE4JBaAqtAC+MxnXTcfx1KwDkohYqWSYWhJ
i0GJw9o6RcFdTGIdlAJVYbzSS1Z8qS3qq8Joy3vmFcv8CNLNa7BApoaqkB1bpdTRMbfvNGJZWhRr
+TfqmRbtfNHAUVnPRWLM+44BZOjWZN4TDEvMsNM8zc4JzG43dFjm7EEScym2z4JLmhRr5QZHwNgZ
xxSLjSKnKhFoDOH3dKT1Fca7zxa70NJ4RXNf4Zo7jc1EzuownHGRuJmntpSCTjkVS1bVRceushHI
Uvxeiu7G+wAkK7fHYq5SHBo1GMPK8liEZkK3nEbDsHirkAWHNTpB1f1crINkcUEs994rhpuFGrO5
68LXL02BT1xUhQAUywJM454YCTcUbppTh79d+5a2W4r9/RIWBWNdsYalf5E6FbF5heW1o2AU68Ty
eykcD+wdQcOQcWL5bFzdRDuaKkZAKbaJVbGXygkMF12gVBIINyAHKRTLIoBXINYixjdTe2tPj4FU
7BLr+YeovbWHjoBUzBJr+KSHqMciebINs1gHJQ4mI++37yS6BmWEaFOue/Az0IpNxYpNtVF8d+0V
mAkmIdyQqArRLIRiASCWVRgknSeBtGCFBsErBokV622g/A5rj6BhyKDH6qzvoL1QhyaRIoQ5xQr2
eEifknied88EJIu5OFbDeeI5kiOkhyT07f/yHBSLMexkIftGm1d0XiGOJSGOBcVaaMmzMnZgTPTc
kYx5rHsfsSDzhhWjPl9afRGKxQ6mj5Qwcqezo4L3GLLlsaJ7mAkQDU6JHctiSrFCc5a0tixZr7Cx
R2yXxZZi6VrdxOFWoTX3CmIh3ADzzkxNyNY0YyUIYrHxh7pnkqminbxXZJfFUByrxqphDRbNXj72
7I2zUCwGBKvXw1jZ9vcKnC+LHcWqcXewVraPKeJKFjuKtc6yEQMzVp3Ys05cxUK4AeEGoRVLYTOj
WUjYRGxljNxnIEzrnRVce88vbGXIimIdp3dqTuYadVkuy6+AWDRjrMLCzJAWWqymqhEQi2aH1dvl
ZrN89x1QQCyK0drEaPk27RVUsRBuMBtuwHKtTJt3enFb1ivADrGaaR6AcjXrNRuxFiFdFgtxrOHj
9TTfXpHV6crvCIhILBY6ob/Zaq11NzfFvnIJ+XZ4yv/aUVSFFKJasjgzpMVdhe0VP4XHohFfedxs
l/FuEZe3R7gBQLjBIsygCAQk1nUfB6XsGwOxaEPrPAelPP+EAmLRhWDEw0Epe+4Qbk1f2s1789sV
1nss64cm+/zvQ7FoQmzKhsyQNgx5bxNuHRTKiVX+kZuLYnafKhe4KlSXx22nthDHAswqlirLspq1
5TCitmQ/sCWOFYqiKpRoEanquxq4KejaujEQixY0tvHjTNy7joBYC5VhwlqpC0j+cATBa10clbR3
dlhQ8x7nUsqqUzCUu7PkBVuuY9MU+2jniwIRi+YRpF2SPcSyKXXDrCQSsXIqVrp2IdwAmPRYsppw
VurylrOI8RerjgnUFZ0+5j05brtyeSsBx8a87/rAroGXMy6bLnTjm0sINzgNJVDCXWHPnhenx5Da
WTpzLe/YdamIXYrV11P2KRTLWYTCPK4l6T0ZArGcRe3jbg5L2/1JrYDhhtxAuAHgSLH4rTFCIJaT
TcJ7eC3/0DOCxLLorArtXfDS1nTcDK3lyZ9iKXX93Bb4bECMWBaVimXzt9reBQQGOypEIBaVinW8
n+MSbzwOxXLMY9kLLHkihmLZ3my6hfsnhGIlHJbEuQnh/gHpVCylhfcY4sQDAkgWfYo1dMbu1SNt
91gtp/mXLOoUS+m9yH2hv1WngFh2Y6r1CveFXt46iaoQ4QaAD/MOgFgWOKxOB9yHA4IV6+TdZVE2
5n3teIcQ3+fSW0rOQLFshN8riYGu1xUQyz6MT7U6cFUn8rw3lYyAWPYh8JJbEgT7OI84INyAcIMI
HgsAsSxwWMNCFb1vHMSyB8//yJnrOlQTrjkEYtmCYLRBEgkbpCDHT0dRgHT1L5qEIpb03DmOsxrR
o1jBQJtDV3ZqvcL28xxLFkXhhphTubcdCzfEOF4HhSKPJdpqM3w/MTXEGhNuqcgFKNdBLKsd1q8l
EVHPrcuixWN11u4UkVhDk7ymCKFEsYI9vxVSsRp6eJUsSuJYq0MVQhLraMn3OZ2URIlieZy07jMO
XlvxcPqVwbAZDJvhV7FC0wL/Bab5zChAhce6975SJ8vAtgUEcuL3q7l0WTQo1vSREklczAa41Gsa
PJYo+V7zYHCKx8enQLFCzV6ReSU1TvDosijwWH03tQhNrKPdvyzl76kQbkC4gdOqUMEfgccycJxY
yq9C4BWHZeC4x6opfcLpMnA2jhV3mQ9fPwfFIvxlPcBrZ5keeI5wF8ty2rwPTbwIXklS52HeRnc4
rVjbvWBVXLK4eyKEGwA+W4UUYAZFwBuxokP4CyyZzSiIRa5J2OwCoxaxbo6vWJajcayazw/TUAYR
Guh97JFbz/JELCcVS+ndDaVaxr4DXMWynGwVxp4ZAJ9S2OFt4pRYqiTJK/iEcANgBGWZ2rREIxUl
AzDqsZSnaRksQksci54SIatYGcZKXdat+A8rqsPRy/haZ8LdPCqIYskLSP6w4Ovp97rBpUx0+UN8
E8sOwx6uaAWTstBUEeZcsVTVcvvetw+CtQL7RvkmVqIGtPjCr62npgzomUtx/yluiLUyjpWsBxHH
AogpVtKlJ4lkMZ2qgyj6nAhWi9AqtA4NNA0SoWk8VrRBAbFMfC+l9RKQ02XVBvh4EGeGzXzhoam/
NULTqLCnjv8HimXYYUltEpAb7RUXuHiOMicu+pcoYlh50VXPXbghJxBuAFipChFqEKB8HCBWdTcS
zBSC0j2GqtAINj9I2eomtOXH8o2+C8UyIPTXMKu+MNoiHFSG9ivWjgHa8l9Ql9HPF2Y/U4r9itU4
C00qJlmNUCwegBykHCgWjQ1CGnnFfMPZ7r7Cud+cwbdZg8saYX0dFJsVKxbYDtZocVmBGBRLD3a3
vEOhx6Iv501fz9oPoVjaEQojhqUN3nAIxNKOKOYSaoTby3giNoQbEG7gwbwDIBZ5KM10RmfoFCxl
B9Muy86qUPAFL8UqLhvDDcobZ0pBF+347usrDJeXjYoV7aS0z55W895Z8gI8lgbsQdBdH7zz8FhM
A+EGxluFAIhFHr5xFLZujPtArGIYqaK2DOitCav+zOy4LLs8lu8yYlgGsPlNVhfItCuONfcyYlgG
cLnlUh+qwgII1pZT3Cqk99bKmc1qZBOxmg5CfQzhYDs8FrNAHItVj6WseZlmpxCheTlOpeYVJl2W
LYo17H8PimUUzW8z2TC0xWP56R7pTndN2NWigFi54ZOwuomJdk/FCDxWnlPsXQd+GMcnNz6DYuXE
iQbKW4V0317lCZh3hBsA2xQrGEIpm0QoCGKtxKEHwQyTuMZg1lbLiRWM/hvMMIkN0iRahdlwbWii
vQxc1P+Vnjt3CYqVJVjnsbqJebSfD4JYmaifRRoQEi6LuW4dhBsQbmBRsWIoYUFL0lpiBe8GIwhh
E10uS00gfcNWYh3aBUYQQtshuu5HjkNN37CRWMGTyAxJCg0n2WoYWmred6z+AxhBCnStg5KkxcLP
5Q07FWsANSHBupCuiZkJayWnbyDcAJBRrCSv5NwcsVCxmOk4nWHlRikr0WXLLtvbKtw/jC82UQzv
Z+hmrSNWLIAmIVm00tZjWEiyrPNYnRIraUCY6dIZnGIns8qqTKOfZvlNnjjYY7VgqY4cSuBww6dp
7GEnlpU2HkuVKyvV5K9zC5uL7xodjxW4fsziWzcxUizzUJeNVzZ1mqM/3vIKg8SKP2fyWdOrP6OF
+K3laYuIEUtihVjSF68zo1hl+UQa4SvADNLMeyrUtbSlonwAzU1EDYol596XMpjoEzDZnUCoN0L/
aRjqBkE6bsA+YqEKBAiadzlp2RfkVoZ5B8iZdwCwRLHYQUpQVb1NjOVDVROtE/MeevkMuh6ApYqE
RWKlDwGSjR4qG/eSKolvhqS/5Z1v6BNahTRFHIwfTVCv9J2LKddSJrHNLBPFbZQg5v++Mpu1m0jE
klkfO63zAdh52FWs80rCA4BYHPkz3DPf5p15dnP7XWDRY5noIkgdSof+6HoAlSWrj8g7gKoQALEA
EAsAQCwAxAJALAAAsQAQCwCxAADEAkAsAMQCABALALEAEAsAQCyAYvwfqVWQRgrdKZQAAAAASUVO
RK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2011-08-31 16:42:41 -0500" MODIFIED_BY="James M Wright" NO="5" REF_ID="CMP-002.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: Current thiazide users vs nonusers (case-control studies), outcome: Hip Fracture.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-07-31 13:46:13 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-22 00:17:07 -0600" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-21 23:23:07 -0600" MODIFIED_BY="[Empty name]">NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE (COHORT STUDIES)</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-22 00:17:07 -0600" MODIFIED_BY="[Empty name]">
<P>
<U>Note</U>: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories. A maximum of two stars can be given for Comparability</P>
<P> <B>Selection</B>
</P>
<P>1) <U>Representativeness of the exposed cohort</U>
</P>
<P>a) truly representative of the average _______________ (describe) in the community *</P>
<P>b) somewhat representative of the average ______________ in the community *</P>
<P>c) selected group of users e.g. nurses, volunteers</P>
<P>d) no description of the derivation of the cohort</P>
<P>2) <U>Selection of the non exposed cohort</U>
</P>
<P>a) drawn from the same community as the exposed cohort *</P>
<P>b) drawn from a different source</P>
<P>c) no description of the derivation of the non exposed cohort       </P>
<P>3) <U>Ascertainment of exposure</U>
</P>
<P>a) secure record (e.g. surgical records) *</P>
<P>b) structured interview *</P>
<P>c) written self report</P>
<P>d) no description</P>
<P>4) <U>Demonstration that outcome of interest was not present at start of study</U>
</P>
<P>a) yes *</P>
<P>b) no</P>
<P>
<B>Comparability</B>
</P>
<P>1) <U>Comparability of cohorts on the basis of the design or analysis</U>
</P>
<P>a) study controls for _____________ (select the most important factor) *</P>
<P>b) study controls for any additional factor *  (This criteria could be modified to indicate specific control for a second important factor.)           </P>
<P>
<B>Outcome</B>
</P>
<P>1) <U>Assessment of outcome</U>
</P>
<P>a) independent blind assessment *</P>
<P>b) record linkage *</P>
<P>c) self report           </P>
<P>d) no description</P>
<P>2) <U>Was follow-up long enough for outcomes to occur</U>
</P>
<P>a) yes (select an adequate follow up period for outcome of interest) *</P>
<P>b) no</P>
<P>3) <U>Adequacy of follow up of cohorts</U>
</P>
<P>a) complete follow up - all subjects accounted for *</P>
<P>b) subjects lost to follow up unlikely to introduce bias - small number lost - &gt; ____ % (select an adequate %) follow up, or description provided of those lost) *</P>
<P>c) follow up rate &lt; ____% (select an adequate %) and no description of those lost</P>
<P>d) no statement</P>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-11-22 00:17:36 -0600" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-21 23:26:16 -0600" MODIFIED_BY="[Empty name]">NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE (CASE-CONTROL STUDIES)</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-22 00:17:36 -0600" MODIFIED_BY="[Empty name]">
<P>
<U>Note</U>: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories. A maximum of two stars can be given for Comparability.</P>
<P> <B>Selection</B>
</P>
<P>1) <U>Is the case definition adequate</U>?</P>
<P>a) yes, with independent validation *</P>
<P>b) yes, e.g. record linkage or based on self reports</P>
<P>c) no description</P>
<P>2) <U>Representativeness of the cases</U>
</P>
<P>a) consecutive or obviously representative series of cases  *</P>
<P>b) potential for selection biases or not stated</P>
<P>3) <U>Selection of Controls</U>
</P>
<P>a) community controls *</P>
<P>b) hospital controls</P>
<P>c) no description</P>
<P>4) <U>Definition of Controls</U>
</P>
<P>a) no history of disease (endpoint) *</P>
<P>b) no description of source</P>
<P>
<B>Comparability</B>
</P>
<P>1) <U>Comparability of cases and controls on the basis of the design or analysis</U>
</P>
<P>a) study controls for _______________  (Select the most important factor.)  *</P>
<P>b) study controls for any additional factor *  (This criteria could be modified to indicate specific control for a second important factor.)</P>
<P> </P>
<P>
<B>Exposure</B>
</P>
<P>1)<U> Ascertainment of exposure</U>
</P>
<P>a) secure record (e.g. surgical records) *</P>
<P>b) structured interview where blind to case/control status *</P>
<P>c) interview not blinded to case/control status</P>
<P>d) written self report or medical record only</P>
<P>e) no description</P>
<P>2) <U>Same method of ascertainment for cases and controls</U>
</P>
<P>a) yes *</P>
<P>b) no</P>
<P>3) <U>Non-Response rate</U>
</P>
<P>a) same rate for both groups *</P>
<P>b) non respondents described</P>
<P>c) rate different and no designation</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-07-31 13:46:13 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-07-24 18:21:09 -0500" MODIFIED_BY="[Empty name]">Coding manual for Newcastle-Ottawa Quality Assessment Scale</TITLE>
<APPENDIX_BODY MODIFIED="2011-07-31 13:46:13 -0500" MODIFIED_BY="[Empty name]">
<P>  </P>
<P>
<U>
<B>CODING MANUAL FOR COHORT STUDIES</B>
</U>
</P>
<P> </P>
<SUBSECTION>
<HEADING LEVEL="3">SELECTION</HEADING>
<P> </P>
<P>
<B>1)      Representativeness of the Exposed Cohort</B>
</P>
<P> </P>
<P>Item is assessing the representativeness of exposed individuals in the community, not the representativeness of the sample of women from some general population.  For example, subjects derived from groups likely to contain middle class, better educated, health oriented women are likely to be representative of postmenopausal oestrogen users while they are not representative of all women (e.g. members of a health maintenance organisation (HMO) will be a representative sample of oestrogen users.  While the HMO may have an under-representation of ethnic groups, the poor, and poorly educated, these excluded groups are not the predominant users users of oestrogen).</P>
<P> </P>
<P>Allocation of stars as per rating sheet</P>
<P> </P>
<P>
<B>2)      Selection of the Non-Exposed Cohort</B>
</P>
<P> </P>
<P>Allocation of stars as per rating sheet</P>
<P> </P>
<P>
<B>3)      Ascertainment of Exposure</B>
</P>
<P> </P>
<P>Allocation of stars as per rating sheet</P>
<P> </P>
<P>
<B>4)      Demonstration That Outcome of Interest Was Not Present at Start of Study</B>
</P>
<P> </P>
<P>In the case of mortality studies, outcome of interest is still the presence of a disease/ incident, rather than death.  That is to say that a statement of no history of disease or incident earns a star.</P>
<P> </P>
<P>
<B>
<I>COMPARABILITY</I>
</B>
</P>
<P> </P>
<P>
<B>1)      Comparability of Cohorts on the Basis of the Design or Analysis</B>
</P>
<P> </P>
<P>A maximum of 2 stars can be allotted in this category</P>
<P>Either exposed and non-exposed individuals must be matched in the design and/or confounders must be adjusted for in the analysis.  Statements of no differences between groups or that differences were not statistically significant are not sufficient for establishing comparability.  Note: If the relative risk for the exposure of interest is adjusted for the confounders listed, then the groups will be considered to be comparable on each variable used in the adjustment.</P>
<P>There may be multiple ratings for this item for different categories of exposure (e.g. ever vs. never, current vs. previous or never)</P>
<P> Age =  *  , Other controlled factors = *</P>
<P> </P>
<P>
<B>
<I>OUTCOME</I>
</B>
</P>
<P> </P>
<P>
<B>1)      Assessment of Outcome</B>
</P>
<P> </P>
<P>For some outcomes (e.g. fractured hip), reference to the medical record is sufficient to satisfy the requirement for confirmation of the fracture.  This would not be adequate for vertebral fracture outcomes where reference to x-rays would be required.</P>
<P>a)      Independent or blind assessment stated in the paper, or confirmation of the outcome by reference to secure records (x-rays, medical records, etc.) *</P>
<P>b)      Record linkage (e.g. identified through ICD codes on database records) *</P>
<P>c)      Self-report (i.e. no reference to original medical records or x-rays to confirm the outcome)</P>
<P>d)     No description.</P>
<P> </P>
<P>
<B>2)      Was Follow-Up Long Enough for Outcomes to Occur</B>
</P>
<P> </P>
<P>An acceptable length of time should be decided before quality assessment begins (e.g. 5 yrs. for exposure to breast implants)</P>
<P> </P>
<P>
<B>3)      Adequacy of Follow Up of Cohorts</B>
</P>
<P> </P>
<P>This item assesses the follow-up of the exposed and non-exposed cohorts to ensure that losses are not related to either the exposure or the outcome.</P>
<P> </P>
<P>Allocation of stars as per rating sheet</P>
<P> </P>
<P> </P>
<P>
<U>
<B>CODING MANUAL FOR CASE-CONTROL STUDIES</B>
</U>
</P>
<P> </P>
<P>
<B>
<I>SELECTION</I>
</B>
</P>
<P> </P>
<P>
<B>1)      Is the Case Definition Adequate?</B>
</P>
<P>
<B> </B>
</P>
<P>a)      Requires some independent validation (e.g. &gt;1 person/record/time/process to extract information, or reference to primary record source such as x-rays or medical/hospital records) *</P>
<P>b)      Record linkage (e.g. ICD codes in database) or self-report with no reference to primary record</P>
<P>c)      No description</P>
<P> </P>
<P>
<B>2)      Representativeness of the Cases</B>
</P>
<P>
<B> </B>
</P>
<P>a)      All eligible cases with outcome of interest over a defined period of time, all cases in a defined catchment area, all cases in a defined hospital or clinic, group of hospitals, health maintenance organisation, or an appropriate sample of those cases (e.g. random sample) *</P>
<P>b)      Not satisfying requirements in part (a), or not stated.</P>
<P> </P>
<P>
<B>3)      Selection of Controls</B>
</P>
<P>
<B> </B>
</P>
<P>This item assesses whether the control series used in the study is derived from the same population as the cases and essentially would have been cases had the outcome been present.</P>
<P>a)      Community controls (i.e. same community as cases and would be cases if had outcome) *</P>
<P>b)      Hospital controls, within same community as cases (i.e. not another city) but derived from a hospitalised population</P>
<P>c)      No description</P>
<P> </P>
<P>
<B>4)      Definition of Controls</B>
</P>
<P>
<B> </B>
</P>
<P>a)      If cases are first occurrence of outcome, then it must explicitly state that controls have no history of this outcome.  If cases have new (not necessarily first) occurrence of outcome, then controls with previous occurrences of outcome of interest should not be excluded. *</P>
<P>b)      No mention of history of outcome</P>
<P> </P>
<P>
<B>
<I>
<BR/>
</I>
</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">COMPARABILITY</HEADING>
<P> </P>
<P>
<B>1)      Comparability of Cases and Controls on the Basis of the Design or Analysis</B>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3"> </HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">A maximum of 2 stars can be allotted in this category</HEADING>
<P>Either cases and controls must be matched in the design and/or confounders must be adjusted for in the analysis.  Statements of no differences between groups or that differences were not statistically significant are not sufficient for establishing comparability.  Note: If the odds ratio for the exposure of interest is adjusted for the confounders listed, then the groups will be considered to be comparable on each variable used in the adjustment.</P>
<P>There may be multiple ratings for this item for different categories of exposure (e.g. ever vs. never, current vs. previous or never)</P>
<P> Age = *   , Other controlled factors = *</P>
<P> </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EXPOSURE</HEADING>
<P> </P>
<P>
<B>1)      Ascertainment of Exposure</B>
</P>
<P>
<B> </B>
</P>
<P>Allocation of stars as per rating sheet</P>
<P> </P>
<P>
<B>2)      Non-Response Rate</B>
</P>
<P>
<B> </B>
</P>
<P>Allocation of stars as per rating sheet</P>
<P> </P>
<P>     </P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>